



# Nottingham Pathology 2016

9<sup>th</sup> Joint Meeting of the British Division of  
the International Academy of Pathology  
and the Pathological Society  
of Great Britain & Ireland  
**28 June – 1 July 2016**

**Hosted by**

Academic Unit of Molecular Pathology  
Division of Cancer and Stem Cells  
School of Medicine, University of Nottingham

**Venue**

East Midlands Conference Centre and Orchard Hotel  
The University of Nottingham, University Park, NG7 2RJ

**Companion Sessions**

AIDPATH • British Lymphoma Pathology Group  
Association of Clinical Electron Microscopists  
UK Cardiac Pathology Network • Renal EQA



## CONTENTS

---

<b>Programme Overview</b> .....	2
<b>Scientific Sessions Information</b> .....	10
<b>CPD</b> .....	13
<b>Fees and Registration</b> .....	14
<b>General Arrangements</b> .....	16
<b>Future Meetings</b> .....	18
<b>Trade Exhibition / Sponsors</b> .....	19
<b>Detailed Programme</b>	
<b>Tuesday 28 June</b> .....	22
The AIDPATH Project – Advances in Digital Pathology *	
<b>Wednesday 29 June</b> .....	32
The AIDPATH Project – Her2 Automated Scoring Contest *	
<b>Thursday 30 June</b> .....	42
Association of Clinical Electron Microscopists *	
British Lymphoma Pathology Group (BLPG) *	
Renal EQA	
Renal Transplant EQA	
<b>Friday 1 July</b> .....	48
British Lymphoma Pathology Group (BLPG) *	
UK Cardiac Pathology Network *	
<b>Abstract Reviewers</b> .....	51
<b>Index of Presenters and Abstract Numbers</b> .....	52

\* Visit [www.path.org.uk](http://www.path.org.uk) for programme details.

Refer to [www.path.org.uk](http://www.path.org.uk) for Abstract Listings:

- Invited Speakers
- Plenary Oral and Oral
- Posters

---

### Programme acknowledgements

© 2016

This Programme is jointly published by:

The British Division of the International Academy of Pathology  
and The Pathological Society of Great Britain & Ireland

### Cover picture credits:

The publishers wish to thank the following for granting permission to use their photographs:

Top/Main picture.....Photographer – Gerry Molumby

Lower two pictures.....Experience Nottinghamshire

This publication was designed and printed in England by Byte & Type Limited, Birmingham (Tel: 0333 666 4321).

<b>08.00 ▶pg22</b> [Foyer] <b>Registration and Coffee</b>		
<b>08.00–18.00 ▶pg22</b> [Conference Suite 4] <b>Slide Seminar Case Competition Viewing</b>		
<b>08.50–08.55 ▶pg22</b> [Conference Theatre] <b>Welcome Address</b> Prof IO Ellis, Nottingham		
<b>08.55–11.50 ▶pg22</b> [Conference Theatre] <b>Symposium:</b> <i>Gynaecological Pathology</i>  10.30–10.50 [Banqueting Suite] Refreshments and Trade Exhibition	<b>08.55–11.50 ▶pg24</b> [Conference Suite 1] <b>Trainees' Symposium:</b> <i>The Pathologist in the MDT; The Surgical, Oncological, Radiological and Pathological Perspective</i>  10.10–10.40 [Banqueting Suite] Refreshments and Trade Exhibition	
<b>12.00–13.00 ▶pg25</b> [Conference Theatre] <b>BDIAP Kristin Henry Lecture: <i>Evolution of Classifications in Lung Pathology</i></b> Prof AG Nicholson, London		
<b>13.00–14.00 ▶pg25</b> [Banqueting Suite] <b>Lunch, Trade Exhibition and Poster Viewing</b>		
<b>14.00–16.55 ▶pg25</b> [Conference Theatre] <b>Symposium:</b> <i>Journal of Pathology: Models of Human Disease</i>  15.30–15.55 [Banqueting Suite] Refreshments and Trade Exhibition	<b>14.00–17.00 ▶pg28</b> [Conference Suite 1] <b>Symposium:</b> <i>Hepatobiliary Pathology</i>  15.30–15.55 [Banqueting Suite] Refreshments and Trade Exhibition	<b>14.00–17.00 ▶pg29</b> [Conference Suite 2] <b>Symposium:</b> <i>Head and Neck Pathology</i>  15.20–15.45 [Banqueting Suite] Refreshments and Trade Exhibition
<b>17.00–17.50 ▶pg31</b> [Conference Theatre] <b>Public Lecture: <i>The 100,000 Genomes Project – Transforming the NHS?</i></b> Dr TA Fowler, London		
<b>18.30–20.30 ▶pg31</b> [Venue: Nottingham Castle] <b>Welcome Reception and Optional Cave Tour</b> Buses depart at 18.00		

<b>08.55–11.55 ▶pg23</b> [Conference Suite 3] <b>Symposium:</b> <i>Pulmonary Pathology</i>  10.15–10.35 [Banqueting Suite] Refreshments and Trade Exhibition	<b>09.00–12.00 ▶pg24</b> [Gallery 2/3] <b>Undergraduate Day:</b> <i>Undergraduate Engagement Forum</i>  10.30–10.50 [Banqueting Suite] Refreshments and Trade Exhibition	<b>09.00–17.00 ▶pg25</b> [Gallery 1] <b>Symposium:</b> <i>Advances in Digital Pathology: The AIDPATH Project</i>  For programme details visit: <a href="http://www.path.org.uk">www.path.org.uk</a>
<b>14.00–17.00 ▶pg26</b> [Conference Suite 3] <b>Oral Presentations</b>  15.15–15.45 [Banqueting Suite] Refreshments and Trade Exhibition	<b>14.00–16.50 ▶pg29</b> [Gallery 2/3] <b>Undergraduate Day: Undergraduate Presentations and Prize Presentation</b>  15.20–15.45 [Banqueting Suite] Refreshments and Trade Exhibition	

<b>07.30 ▶pg32 [Foyer]</b> <b>Registration and Coffee</b>	
<b>08.00–18.00 ▶pg32 [Conference Suite 4]</b> <b>Slide Seminar Case Competition Viewing</b>	
<b>08.55–11.50 ▶pg32</b> [Conference Theatre] <b>Symposium: <i>Gastrointestinal Pathology</i></b>	<b>08.55–12.00 ▶pg34</b> [Conference Suite 1] <b>Symposium: <i>Genitourinary Pathology</i></b>
10.30–10.50 [Banqueting Suite] Refreshments and Trade Exhibition	10.30–10.50 [Banqueting Suite] Refreshments and Trade Exhibition
<b>12.00–13.00 ▶pg34 [Conference Theatre]</b> <b>Pathological Society CL Oakley Lecture:</b> <b><i>Quantifying Clonal Evolution in the Human Colon</i></b> Dr TA Graham, London	
<b>13.00–14.00 ▶pg34 [Banqueting Suite]</b> <b>Lunch, Trade Exhibition and Poster Viewing</b>	
<b>14.00–17.00 ▶pg35</b> [Conference Theatre] <b>Oral Presentations — 1</b>	<b>14.00–17.00 ▶pg39</b> [Conference Suite 1] <b>Oral Presentations — 3</b>
15.15–15.45 [Banqueting Suite] Refreshments and Trade Exhibition	15.15–15.45 [Banqueting Suite] Refreshments and Trade Exhibition
<b>17.00–18.30 ▶pg41 [Banqueting Suite]</b> <b>Poster Viewing, Chairman's Rounds and Refreshments</b>	

<b>08.00–08.55 ▶pg32</b> [Conference Suite 3] <b>Trainees' Meet The Experts:</b> <b><i>Dermatopathology</i></b> Light breakfast will be provided	<b>09.00–17.00 ▶pg40 [Gallery 1]</b> <b>Symposium:</b> <b><i>The AIDPATH Project: Her2 Automated Scoring Contest</i></b>  For programme details visit: <a href="http://www.path.org.uk">www.path.org.uk</a>
<b>08.55–12.00 ▶pg33</b> [Conference Suite 3] <b>Symposium: <i>Breast Pathology</i></b>	
10.30–10.50 [Banqueting Suite] Refreshments and Trade Exhibition	
11.20–11.50 Royal College of Pathologists: Neera Patel Lecture	
<b>14.00–17.00 ▶pg37</b> [Conference Suite 3] <b>Oral Presentations — 2</b>	
15.15–15.45 [Banqueting Suite] Refreshments and Trade Exhibition	

07.30 ▶pg42 [Foyer] <b>Registration and Coffee</b>	
08.00–18.00 ▶pg42 [Conference Suite 4] <b>Slide Seminar Case Competition Viewing</b>	
08.55–12.00 ▶pg42 [Conference Theatre] <b>Symposium:</b> <i>Mechanisms of Disease: Cutting Edge Topics</i>	08.00–08.55 ▶pg42 [Conference Suite 1] <b>Trainees' Meet The Experts:</b> <i>GI-Sessile Serrated Lesions</i> Light breakfast will be provided
	08.55–12.00 ▶pg43 [Conference Suite 1] <b>Symposium:</b> <i>Musculoskeletal Pathology</i>
10.30–11.00 [Banqueting Suite] Refreshments and Trade Exhibition	10.30–11.00 [Banqueting Suite] Refreshments and Trade Exhibition
12.00–13.00 ▶pg45 [Atrium] <b>Trainees' Networking Lunch</b>	
12.00–14.00 ▶pg45 [Banqueting Suite] <b>Lunch, Trade Exhibition and Poster Viewing</b>	
13.00–14.00 ▶pg45 [Gallery 1] <b>Pathological Society Annual General Meeting</b>	
14.00–16.30 ▶pg45 [Conference Theatre] <b>Plenary Oral Presentations</b>	
15.00–15.30 [Banqueting Suite] Refreshments and Trade Exhibition	
16.45–17.30 ▶pg47 [Conference Theatre] <b>Pathological Society Doniach Lecture: <i>Looking at Breast Cancer</i></b> Prof IO Ellis, Nottingham	
19.00–23.00 ▶pg47 [Banqueting Suite] <b>Conference Dinner — including Dodgems and Musical Entertainment</b>	

08.25–12.30 ▶pg44 [Conference Suite 2] <b>Symposium:</b> <i>Renal Pathology</i>	09.30–17.00 ▶pg44 [Gallery 2/3] <b>British Lymphoma Pathology Group (BLPG) Meeting</b>  For programme details visit: <a href="http://www.path.org.uk">www.path.org.uk</a>
10.30–10.50 [Banqueting Suite] Refreshments and Trade Exhibition	
13.30–16.00 ▶pg45 [Conference Suite 2] <b>Association of Clinical Electron Microscopists (ACEM) Meeting</b>  For programme details visit: <a href="http://www.path.org.uk">www.path.org.uk</a>	

08.00 ▶pg48 [Foyer]

**Registration and Coffee**

09.55–16.30 ▶pg49

[Conference Suite 3]

In association with the Royal College of Pathologists

**Symposium:*****Molecular Pathology: Transformative Technologies***

11.00–11.30 [Atrium]

Refreshments

12.30–13.30 [Atrium]

Lunch

15.00–15.30 [Atrium]

Refreshments

08.30–10.00 ▶pg48

[Conference Suite 4]

**Trainees' Slide Seminar Discussion and Case Competiton Winners**

09.00–17.00 ▶pg48

[Gallery 1]

**UK Cardiac Pathology Network Meeting**For programme details visit: [www.path.org.uk](http://www.path.org.uk)

09.00–14.45 ▶pg48

[Gallery 2/3]

**British Lymphoma Pathology Group (BLPG) Meeting**For programme details visit: [www.path.org.uk](http://www.path.org.uk)

**COMPANION MEETINGS AND SATELLITE SESSIONS****Tuesday 28 June**

09.00–17.00 [Gallery 1]

*Advances in Digital Pathology – The AIDPATH Project***Wednesday 29 June**

09.00–17.00 [Gallery 1]

*The AIDPATH Project: Her2 Automated Scoring Contest***Thursday 30 June**

09.30–17.00 [Gallery 2/3]

British Lymphoma Pathology Group

13.30–16.00 [Conference Suite 2]

Association of Clinical Electron Microscopists

**Friday 1 July**

09.00–14.45 [Gallery 2/3]

British Lymphoma Pathology Group

09.00–16.00 [Gallery 1]

UK Cardiac Pathology Group

**KEYNOTE AND NAMED LECTURES** [Conference Theatre]**Tuesday 28 June**12.00–13.00 **Kristin Henry Lecture:** *Evolution of Classifications in Lung Pathology*  
Prof AG Nicholson, London17.00–17.50 **Public Lecture:** *The 100,000 Genomes Project – Transforming the NHS?*  
Dr T Fowler, London**Wednesday 29 June**12.00–12.45 **CL Oakley Lecture:** *Quantifying Clonal Evolution in the Human Colon*  
Dr TA Graham, London**Thursday 30 June**16.45–17.30 **Doniach Lecture:** *Looking at Breast Cancer*  
Prof IO Ellis, Nottingham**ORAL PRESENTATIONS**

Sessions will be held as follows:

Tuesday 28 June 14.00–17.00 [Conference Suite]

Wednesday 29 June 14.00–17.00 [Conference Theatre, Conference Suites 1 &amp; 3]

**Note to presenters:** Speakers are reminded that no communication may exceed the time allocated on the programme without the consent of the meeting, obtained through the Chairman.**PLENARY ORAL SESSION** [Conference Theatre]

The eight highest-ranked submitted oral abstracts will be presented on Thursday 30 June 14.00–16.30.

**Prize:** A prize for the best presentation, donated by the *Journal of Pathology* will be presented at the Conference Dinner.**POSTERS, VIEWING AND CHAIRMAN'S ROUNDS** [Banqueting Suite]**Poster Size**

Poster boards will be size A0 portrait (1189 mm x 841 mm). Please do not exceed these dimensions. Fixings will be provided.

For information on the poster printing service visit: [www.path.org.uk](http://www.path.org.uk)**Viewing**

Delegates are encouraged to visit the posters during break times and lunchtimes as well as during the official rounds.

**Formal Poster Viewing, Chairman's Rounds and Drinks Reception**

Wednesday 29 June 17.00–18.30

Poster round chairs will be circulating during these times to select the winners of the following prizes.

**Prizes****BDIAP Poster Prizes:** Awarded for the best 3 posters relevant to Diagnostic Pathology.**Pathological Society:** The Pathological Society's Sir Alastair Currie Prize and Second and Third poster prizes.

Winners will be announced at the Conference Dinner on 30 June.

**Note to presenters**

Ideally, posters should be in place by 09.00 hrs on Tuesday 28 June and must be removed by 15.30 hrs on Thursday 30 June.

**Presentation**The presenting author (or another contributor) must attend the meeting and present the poster during the allocated poster rounds in order for the abstract to be published in the *Journal of Pathology On-Line Supplement* after the meeting.**SLIDE SEMINAR COMPETITION VIEWING AND SESSION****Viewing Virtual Slides** [Conference Suite 4]

Slides images will be available for viewing on:

Tuesday 28 June 08.00–18.00

Wednesday 29 June 08.00–18.00

Thursday 30 June 08.00–18.00 (*Please note the competition closes at 16.00 on Thu 30 June*)

**Competition**

There will be a slide competition using slide images, which will be available during the days/times shown above and will be available on-line in advance of the meeting.

**Prize**

The prize is a case of champagne. The winner will be announced at the Conference Dinner on Thursday 30 June — *at the discretion of the winner, by tradition, this is shared amongst those present at the dinner!*

**Competition Case Discussion Session** [Conference Suite 4]

Friday 1 July 08.30–10.00

**SYMPOSIA****Tuesday 28 June**

08.55–11.50 [Conference Theatre] *Gynaecological Pathology*  
 08.55–11.55 [Conference Suite 3] *Pulmonary Pathology*  
 14.00–17.00 [Conference Theatre] *Journal of Pathology: Models of Human Disease*  
 14.00–17.00 [Conference Suite 1] *Hepatobiliary Pathology*  
 14.00–17.00 [Conference Suite 2] *Head and Neck Pathology*

**Wednesday 29 June**

08.55–11.50 [Conference Theatre] *Gastrointestinal Pathology*  
 08.55–11.50 [Conference Suite 3] *Breast Pathology*  
 08.55–12.00 [Conference Suite 1] *Genitourinary Pathology*

**Thursday 30 June**

08.55–12.00 [Conference Theatre] *Mechanisms of Disease – Cutting Edge Topics*  
 08.55–12.00 [Conference Suite 1] *Musculoskeletal Pathology*  
 08.25–12.30 [Conference Suite 2] *Renal Pathology including Renal and Renal Transplant EQA*

**Friday 1 July**

09.55–16.30 [Conference Suite 3] *Transformative Technologies (in association with the Royal College of Pathologists)*

**TRAINEES PROGRAMME****Tuesday 28 June**

08.55–11.50 [Conference Suite 1] *Symposium: The Pathologist in the MDT*

**Wednesday 29 June**

08.00–09.00 [Conference Suite 3] *Breakfast Session: Meet the Experts – Dermatopathology*  
*Light breakfast will be provided.*

**Thursday 30 June**

08.00–09.00 [Conference Suite 1] *Meet the Experts – GI-Sessile Serrated Lesions*  
*Light breakfast will be provided.*

**Friday 1 July**

08.30–10.00 [Conference Suite 4] *Competition Case Discussion Session*

**UNDERGRADUATE DAY****Tuesday 28 June**

09.00–16.50 [Gallery 2/3] *Undergraduate Day*

**CONTINUING PROFESSIONAL DEVELOPMENT (CPD)****Royal College of Pathologists**

This Meeting has been approved by the Royal College of Pathologists for the purpose of Continuing Professional Development. The following credits will be awarded:

	<b>Full Day*</b>
Tuesday 28 June	6 credits
Wednesday 29 June	6 credits
Thursday 30 June	6 credits
Friday 1 July	4 credits

*\*The Society is not permitted to issue certificates for less than full day attendance.*

Delegates should use their reflective notes section of their CPD Portfolio to self-accredit if attending less than full days.

**TRADE EXHIBITION** [The Banqueting Suite]

Delegates are encouraged to visit the Trade Exhibition and are requested to support the companies represented there.



EARLY BIRD REGISTRATION FEES UNTIL MIDNIGHT ON MONDAY 23 MAY 2016			
Delegate Type	Fee Categories	Per Day or Part Day	Conference Dinner
BDIAP or Pathological Society Member	Ordinary Member, Consultant and/or equivalent position	£ 115	£ 60
BDIAP or Pathological Society Concessionary Member	Biomedical Scientist; Honorary or Senior Member; PhD Student; Post-Doctoral Fellow, Technician and Trainee	£ 38	£ 60
Pathological Society Undergraduate Student Member	Undergraduate Student	Free	£ 30
Non-Member	Consultant and/or equivalent position	£ 165	£ 60
Non-Member Concessionary *	Biomedical Scientist; PhD Student; Post-Doctoral Fellow, Technician and Trainee	£ 53	£ 60
Non-Member Undergraduate Student * <i>See special offer below</i>	Undergraduate Student	£ 53	£ 60

### \* CONCESSIONS

Delegates from categories: **Non-Member Undergraduate Student** and **Non-Member Concessionary** must provide an identification document as proof of their student or trainee status, including NTN where applicable. Proof must be by way of a statement from the Head of Department.

Please email to: [julie@pathsoc.org](mailto:julie@pathsoc.org) (see registration website for template wording).

### SPECIAL OFFER: NON-MEMBER UK UNDERGRADUATE STUDENTS

Join the **Royal College of Pathologists** and get free membership of the **Pathological Society** to benefit from free meeting registration for Nottingham Pathology 2016 and all future Pathological Society scientific meetings.

For more information use the URLs below:

<https://www.rcpath.org/discover-pathology/are-you-an-undergraduate-.html>

<http://www.pathsoc.org/index.php/about/undergraduates>

LATE REGISTRATION FEES FROM MIDNIGHT ON TUESDAY 24 MAY 2016			
Delegate Type	Fee Categories	Per Day or Part Day	Conference Dinner
BDIAP or Pathological Society Member	Ordinary Member, Consultant and/or equivalent position	£ 170	£ 80
BDIAP or Pathological Society Concessionary Member	Biomedical Scientist; Honorary or Senior Member; PhD Student; Post-Doctoral Fellow, Technician and Trainee	£ 60	£ 80
Pathological Society Undergraduate Student Member	Undergraduate Student	Free	£ 30
Non-Member	Consultant and/or equivalent position	£ 250	£ 80
Non-Member Concessionary *	Biomedical Scientist; PhD Student; Post-Doctoral Fellow, Technician and Trainee	£ 80	£ 80
Non-Member Undergraduate Student * <i>See special offer</i>	Undergraduate Student	£ 80	£ 80

### REGISTRATION

Registration is **online only** via: [www.path.org.uk](http://www.path.org.uk)

### ADVANCE REGISTRATION

**Advance registration will close on Monday 13 June 2016 (midnight).**

Thereafter delegates may only register **on-site on arrival at the meeting.**

### CANCELLATIONS

A cancellation fee of £20 will be deducted from any refund due for cancellations received in writing by Wednesday 8 June 2016. **No refunds will be made after Wednesday 8 June 2016.**

### REFRESHMENTS

All refreshments, including lunch, are included in the daily registration fee.

### DELEGATE ENROLMENT (AT THE MEETING)

Enrolment at the Delegate Reception Desk will take place from 08.00 hrs each day unless stated otherwise.

## ENQUIRIES

### Meeting website

[www.path.org.uk](http://www.path.org.uk)

### British Division of the International Academy of Pathology

Address PO Box 73, Westbury-on-Trym, Bristol BS9 1RY

Telephone +44 (0)117 907 7940

Fax +44 (0)117 907 7941

E-mail [bdiap@blueyonder.co.uk](mailto:bdiap@blueyonder.co.uk)

### Pathological Society of Great Britain & Ireland

Address 150 Minories, London EC3N 1LS

Telephone +44 (0)20 7347 5751 or 5752

E-mail [admin@pathsoc.org](mailto:admin@pathsoc.org)

## PRESENTATIONS

### Presentation Checking and Preview [Conference Suite 4]

Presentation Checking and Preview will only be available from Tuesday 28 June to Thursday 30 June.

### Oral Presentations/Lectures

**Presentation format:** Powerpoint only, must be PC compatible and must be on a USB.

Presenters must attend their nominated lecture theatre 30 minutes before their presentation time.

## INTERNET ACCESS

Wireless access will be generally available.

PCs and Internet access will only be available in Conference Suite 4.

## MESSAGES

During the Meeting, messages for delegates may be left at the following telephone number: +44 (0)7964 024118.

There will also be a message board located beside the Registration Desk.

## REFRESHMENTS

All refreshments will be served in the Banqueting Suite unless stated otherwise.

## BADGES

Delegates are requested to wear their badges **at all times**.

## COATS AND BAGS

Secure facilities will be provided for coats and bags located on the ground floor.

## TRAVEL

Please refer to the website: [www.path.org.uk](http://www.path.org.uk)

## ACCOMMODATION

Discounted hotel and university accommodation has been organised for delegates, please refer to the website: [www.path.org.uk](http://www.path.org.uk)

## DISCLAIMER

The British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland cannot be held responsible for any injury or loss sustained during the Meeting.

## SOCIAL ACTIVITIES

### Tuesday 28 June

18.30–20.30 [Nottingham Castle] Welcome Reception and Optional Cave Tour.  
*Places are limited – please reserve your free ticket when registering.  
Cave Tour £5.00 per ticket. Buses will depart at 18.00.*

### Thursday 30 June

19.00–23.00 [Banqueting Suite] Conference Dinner and Entertainment.  
*Entertainment provided by “Mood Indigo” and Dodgems.  
Please reserve your ticket when registering (see pages 14–15 for costs).  
Places are limited.*

## Local Places of Interest

For more information please refer to the website: [www.path.org.uk](http://www.path.org.uk)

## FUTURE MEETINGS

## British Division of the IAP

- 2016 25–30 September, Cologne  
*Joint IAP / ESP Congress*
- 2016 2–3 December, London  
*Upper GI and Pancreatobiliary*

## Pathological Society

- 2016 18–21 September, Nottingham  
*2<sup>nd</sup> Residential Training School for Diagnostic Molecular Pathology*
- 2017 19–20 January, London  
*Winter Meeting*
- 2017 6–10 February, London  
*Winter School*

## Joint Meetings of the British Division of the IAP and the Pathological Society

- 2016 19–20 August, London  
*Pathology Summer School for Medical Students*  
*(co-organised and sponsored with the Royal College of Pathologists)*
- 2017 20–23 June, Belfast  
*Belfast Pathology 2017*
- 2018 19–22 June, Maastricht  
*Maastricht Pathology 2018*

## TRADE EXHIBITION

*Correct at time of going to press*

The British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland wish to acknowledge the support of the following companies:

## BIOCARTIS NV

Biocartis aims to provide direct access to personalized medicine for patients worldwide by developing fully integrated, broadly applicable molecular diagnostics. Biocartis' MDx Idylla™ platform, launched in September 2014, is a fully automated sample-to-result, real-time Polymerase Chain Reaction system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. Today, Biocartis has four oncology tests and one infectious disease test on the market. More information: [www.biocartis.com](http://www.biocartis.com) Follow us at: @Biocartis

## DAKO-AGILENT TECHNOLOGIES PATHOLOGY SOLUTION

Whether you are interested in protein or genetic markers, the team from Agilent Technologies can help. Products for routine clinical pathology includes Dako reagents and instruments for IHC and ISH including new PD-L1 CE-IVD PharmDx IHC kits and a new panel of CE-IVD SureFISH probes for lung cancer (Alk, Ros, Ret and Met). If you are interested in research or testing using any aspect of genomics products we can offer helpful advice and a variety of products from sample QC to NGS panels and data analysis software. Can't get the probe you need? Talk to us about customization to tailor products to your research.

## GE HEALTHCARE

## The Omnyx® Precision Solution™

By combining the technology innovation and backing of GE Healthcare with the pathology expertise and insight of the University of Pittsburgh Medical Center (UPMC), Omnyx offers:

- ▶ Whole slide scanners and integrated software platform deliver scale and reliability for your demanding pathology labs
- ▶ Open doors to improve efficiencies, enhance access to peers and new digital tools
- ▶ Designed as an enterprise-class IT system, Omnyx enables flexible and scalable configuration

Visit our website: [www.gehealthcare.com/digital\\_pathology](http://www.gehealthcare.com/digital_pathology)

or contact : **Tim Wing**, Senior Sales Executive – Digital Pathology, GE Healthcare IT.  
Telephone: +44 (0)7785 375822 Email: [tim.wing@med.ge.com](mailto:tim.wing@med.ge.com)

## GENERON LTD

Generon commercialises reagents (antibodies, recombinants, ELISA kits, RNAi, cDNA clones, probes, PCR/qPCR reagents...) to diagnostic and research labs. As a very dynamic company, we do our best to be close to our customers' needs in terms of high quality reagents that we propose and in terms of service that we provide (search for a particular antibody, technical support, delivery time, etc).

**GENOMIC HEALTH UK LTD**

Genomic Health is a leading provider of genomic-based diagnostic tests than inform treatment decisions and help to ensure each patient receives appropriate treatment for early stage cancer. The company is applying its state-of-the-art scientific and commercial expertise and infrastructure to translate significant amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from screening and surveillance, through diagnosis and treatment selection. The company is based in Redwood City, California with UK headquarters in London. For more information please visit: [www.Genomichealth.co.uk](http://www.Genomichealth.co.uk)

**LEEC LTD**

LEEC, based in Nottingham, are internationally recognised for the design, manufacture and supply of Laboratory, Pathology and Forensic equipment into Hospital Mortuaries, Histopathology Laboratories, and Research Centres. Working closely with our customers, we aim to provide bespoke equipment that is designed with end user need's in mind. Ventilated Benches, Staining Tables and Grossing Stations provide practical, ergonomic and safe solutions. ISO9001 accredited, LEEC can offer a total and professional service, with a wealth of experience in the design, supply and installation of equipment for your existing or new laboratory. Winners of The Queen's Award for Enterprise: International Trade 2016. [www.leec.co.uk](http://www.leec.co.uk)

**THE NEWCASTLE MOLECULAR PATHOLOGY NODE**

The Newcastle Molecular Pathology Node is an exciting partnership between Newcastle University and Newcastle Upon Tyne Hospitals (NUTH) and the NHS Foundation Trust which aims to drive advances in Molecular Pathology and bring research back into the heart of pathology laboratories. Funded by the Medical Research Council (MRC) and Engineering and Physical Sciences Research Council (EPSRC), the Newcastle Molecular Pathology Node has been established to address key challenges currently facing Molecular Pathology in order to support the development of stratified medicine in the UK.

**ROCHE TISSUE DIAGNOSTICS**

Headquartered in Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. *(All trademarks used or mentioned are protected by law.)*

**PERKIN ELMER**

Perkin Elmer is a global leader focused on improving the health and safety of people and the environment. Following the 2011 acquisition of Chemagen GmbH by Perkin Elmer, chemagen nucleic acid extraction technology has extended and advanced

Perkin Elmer's offerings into the molecular research and diagnostic areas. The chemagic kit products contain proprietary magnetic particles with a high affinity to nucleic acids and low protein binding. These kits are used with the chemagic automated instruments and are an ideal solution for isolating nucleic acids from a wide variety of sample types including FFPE tissue, blood, cells and saliva.

**SECTRA LTD**

Sectra provides a complete solution for primary diagnostics in digital pathology, including archiving and an advanced review workstation. Sectra pathology PACS is built on the same infrastructure as our radiology PACS, enabling bi-directional sharing of images and reports, and creating a transparency across cancer care pathways. This transparency allows for correlation of findings and provides a broader view of patient disease for physicians to make more accurate diagnosis and treatment decisions. Another benefit of having radiology and pathology PACS built on the same infrastructure is the reduced two-system maintenance and operating costs.

**SILICON BIOSYSTEMS**

Silicon Biosystems, with offices in Bologna Italy and San Diego has developed an instrument platform for cell and molecular biology which can sort, manipulate, and collect individual or groups of rare cells. Using a proprietary electronic chip-based microfluidic cartridge and microscopic image analysis the DEPArray™ system can recover cells, single or in pool, with 100% purity, allowing downstream molecular analyses such as whole genome amplification and sequencing. The technology has application in the molecular characterization of circulating tumor cells, tumor infiltrating cells, FNA and FFPE tissues. The DEPArray™ system resolves cellular heterogeneity, enabling precise NGS profiling of pure cell subpopulations.

**SYSMEX UK**

A global leader in diagnostic solutions. Developing advanced molecular technologies such as OSNA® to provide highly accurate and standardized sentinel lymph node analysis for breast cancer patients and reliable lymph node staging and optimised treatment decisions for colon cancer patients. Sysmex UK are also the UK partner for 3DHISTECH digital pathology solutions; outstanding quality, wide range of slide scanners and world class automated microarray solutions. The new Panoramic P250 III slide scanner is the latest and fastest slide scanner available today.

**WILEY**

Wiley proudly publishes *The Journal of Pathology* and the new open access title *The Journal of Pathology: Clinical Research* on behalf of the **Pathological Society**, and *Histopathology* on behalf of the **British Division of the International Academy of Pathology**. Wiley is the leading society publisher, offering libraries and individuals 1250 online journals, thousands of books and e-books, reviews, reference works, databases, and more. For more information please visit [www.wiley.com](http://www.wiley.com), or our online resource: [onlinelibrary.wiley.com](http://onlinelibrary.wiley.com).

▶ 08.00

Foyer

**REGISTRATION and COFFEE**

▶ 08.00 – 18.00

Conference Suite 4

**SLIDE SEMINAR CASE COMPETITION VIEWING**

▶ 08.50 – 08.55

Conference Theatre

**WELCOME ADDRESS**

Prof IO Ellis  
University of Nottingham, Nottingham, UK

▶ 08.55 – 11.50

Conference Theatre

**SYMPOSIUM****Gynaecological Pathology**

Chair: Prof MJ Arends, University of Edinburgh, Edinburgh, UK  
Dr S Deen, Nottingham University Hospitals NHS Trust, Nottingham, UK

- 09.00–09.30 **[S1] Early Detection Biomarkers and Risk Estimation Models for Ovarian Cancer**  
MR Russell<sup>1</sup>; A D'Amato<sup>1</sup>; A Gentry-Maharaj<sup>2</sup>; A Ryan<sup>2</sup>; J Kalsi<sup>2</sup>; U Menon<sup>2</sup>; I Jacobs<sup>3</sup>; © Dr RLJ Graham<sup>1</sup>  
<sup>1</sup>University of Manchester, Manchester, UK; <sup>2</sup>University College London, London, UK;  
<sup>3</sup>University of New South Wales, Sydney, Australia

- 09.30–10.00 **Angiogenesis in Ovarian Cancer**  
Dr N Nicum  
Oxford University Hospitals NHS Foundation Trust, Oxford, UK

- 10.00–10.30 **[S2] Molecular Stratification of Vulval Cancer and its Precursors**  
Prof CS Herrington  
University of Edinburgh, Edinburgh, UK

- 10.30–10.50 **REFRESHMENTS and TRADE EXHIBITION** [Banqueting Suite]

- 10.50–11.20 **[S3] Cervical Neoplasia: Mechanisms of Disease Progression, Biomarkers and Therapeutic Targets**  
Prof J Doorbar  
University of Cambridge, Cambridge, UK

- 11.20–11.50 **[S4] Molecular Pathology of Endometrial Cancer**  
Prof MJ Arends  
University of Edinburgh, Edinburgh, UK

▶ 08.55 – 11.50

Conference Suite 3

**SYMPOSIUM****Pulmonary Pathology**

Chair: Prof AG Nicholson, Royal Brompton Hospital, London  
Dr I Soomro, empath Cellular Pathology Services, Nottingham

- 09.00–09.15 **Introduction**  
Prof AG Nicholson  
Royal Brompton Hospital, London, UK
- 09.15–09.45 **Targeting the Genetic Pathology of Lung Cancer: Where we are and where we are going?**  
Dr JPC LeQuesne  
University of Leicester, Leicester, UK
- 09.45–10.15 **[S5] Immunotherapy, Lung Cancer and Pathology**  
Prof KM Kerr  
Aberdeen University Medical School, Aberdeen, UK
- 10.15–10.35 **REFRESHMENTS and TRADE EXHIBITION** [Banqueting Suite]
- 10.35–11.05 **[S6] Diagnostic Pathology of Lung Cancer in 2016: Managing the Challenge and Getting the Answers**  
Prof JR Gosney  
Royal Liverpool University Hospital, Liverpool, UK
- 11.05–11.35 **[S7] The LungPath Study: Variation in Lung Cancer Pathological Diagnostic Practice in England and How Quality May be Improved**  
Dr PJ Cane  
Guy's and St Thomas' Hospital, London, UK
- 11.35–11.55 **Panel Discussion and Concluding Comments**  
Prof AG Nicholson  
Royal Brompton Hospital, London

▶ 08.55 – 11.50

Conference Suite 1

**TRAINEES' SYMPOSIUM*****The Pathologist in the MDT; The Surgical, Oncological, Radiological and Pathological Perspective***

Chair: Dr K Allen, Leeds Teaching Hospitals, Leeds, UK  
 Dr C Young, Leeds Teaching Hospitals, Leeds, UK

08.55–11.50

**[S8] *Trainees' Symposium: The Pathologist in the MDT***

Prof AM Hanby<sup>2</sup>; Prof D Dodwell<sup>1</sup>; Mr K Horgan<sup>1</sup>; Dr N Sharma<sup>1</sup>  
<sup>1</sup>Leeds Teaching Hospitals NHS Trust, Leeds, UK; <sup>2</sup>Leeds Institute of Cancer and Pathology (LICAP), Leeds, UK

▶ 09.00 – 12.00

Gallery 2 / 3

**UNDERGRADUATE DAY*****Undergraduate Engagement Forum***

Chair: Dr RJ Byers, University of Manchester, Manchester, UK  
 Mr C Slater, University of Manchester, Manchester, UK

09.15–09.45

**[S9] *The Undergraduate Strategy for the Pathological Society of Great Britain & Ireland***

Prof P Quirke  
 Leeds University, Leeds, UK

09.45–10.00

***Undergraduate Sub-Committee: How PathSoc Supports Student Societies***

10.00–10.30

***Undergraduates and National Pathology Week***

Dr S Lishman, President, Royal College of Pathologists, London, UK

10.30–10.50

**REFRESHMENTS and TRADE EXHIBITION** [Banqueting Suite]

10.50–11.10

**[S10] *A Research Career in Pathology***

Dr NP West  
 University of Leeds, Leeds, UK

11.10–11.30

***Training in Histopathology***

Dr A McGregor  
 University Hospitals of Leicester, Leicester, UK

11.30–12.00

**[S11] *Molecular Pathology: From Discovery to Test***

© Prof AJ Freemont; DC Mangham; K Boylan  
 University of Manchester, Manchester, UK

▶ 09.00 – 17.00

Gallery 1

**SYMPOSIUM*****Advances in Digital Pathology: The AIDPATH Project***  
 For programme details visit: [www.path.org.uk](http://www.path.org.uk)

▶ 12.00 – 13.00

Conference Theatre

**BDIAP KRISTIN HENRY LECTURE**

Chair: Dr AJ Howat, President, BDIAP; Royal Blackburn Hospital, Blackburn, UK

**[S12] *Evolution of Classifications in Lung Pathology***

Prof AG Nicholson  
 Royal Brompton and Harefield NHS Foundation Trust, London, UK

▶ 13.00 – 14.00

Banqueting Suite

**LUNCH, TRADE EXHIBITION and POSTER VIEWING**

▶ 14.00 – 16.55

Conference Theatre

**SYMPOSIUM*****Journal of Pathology: Models of Human Disease***

Chair: Prof CS Herrington, Editor in Chief, *Journal of Pathology*;  
 University of Edinburgh, Edinburgh, UK  
 Prof MJ Arends, Editorial Board, *Journal of Pathology*;  
 University of Edinburgh, Edinburgh, UK

14.00–14.30

***Mouse Models of Intestinal Cancer***

Prof O Sansom  
 CRUK Beaton Institute, Glasgow, UK

14.30–15.00

**[S13] *Models of Endometriosis***

C Barbara; C King; A Prentice; J Brenton; © Prof DS Charnock-Jones  
 University of Cambridge, Cambridge, UK

15.00–15.30

**[S14] *Engineering Large Animal Models of Human Disease***

Prof CBA Whitelaw  
 University of Edinburgh, Edinburgh, UK

15.30–15.55

**REFRESHMENTS and TRADE EXHIBITION** [Banqueting Suite]

15.55–16.25

**[S15] *Models of Human Papillomavirus-Associated Disease***

Prof J Doorbar  
 University of Cambridge, Cambridge, UK

16.25–16.55

**[S16] *Cross-Species Models of Human Melanoma***

Dr DJ Adams  
 Wellcome Trust Sanger Institute, Hinxton, UK

▶ 14.00 – 17.00

Conference Suite 3

## ORAL PRESENTATIONS

**Cardiovascular/Pulmonary; Education and Audit**

Chair: Dr L Browning, Oxford, UK  
Prof DM Berney, London, UK

- 14.00–14.15 **[O1] Expression of MET and SOX-2 in Non Small Cell Lung Cancer with Correlation of Histological Features**  
 © AM Quinn<sup>1</sup>; D Ganguli<sup>2</sup>; L Franklin<sup>3</sup>; C Keeling<sup>4</sup>; H Bradley<sup>3</sup>; J Harris<sup>2</sup>; R Byers<sup>4</sup>; D Nonaka<sup>5</sup>; W Newman<sup>2</sup>; F Blackhall<sup>5</sup>  
<sup>1</sup>University Hospital South Manchester, Manchester, UK; <sup>2</sup>Genomic Medicine, St. Mary's Hospital, Manchester, UK; <sup>3</sup>Cancer Research UK, Manchester, UK; <sup>4</sup>Manchester Royal Infirmary, Manchester, UK; <sup>5</sup>Christie Hospital, Manchester, UK
- 14.15–14.30 **[O2] Histopathological Assessment of EBUS Specimens: The Nottingham Experience**  
 © A Loona<sup>1</sup>; R Rummery<sup>2</sup>; D Baldwin<sup>1</sup>; IN Soomro<sup>1</sup>  
<sup>1</sup>Nottingham University Hospitals NHS Trust, Nottingham, UK; <sup>2</sup>Royal Derby Hospital NHS Foundation Trust, Derby, UK
- 14.30–14.45 **[O3] Impact Evaluation of BDIAP / IBMS Sponsored Training Workshops in Basic Histology and Immunohistochemistry in East Africa**  
 © O Rotimi<sup>1</sup>; P Jackson<sup>1</sup>; E Vuhahula<sup>2</sup>; A Kalebi<sup>3</sup>; AJ Howat<sup>4</sup>  
<sup>1</sup>St James's University Teaching Hospital, Leeds, UK; <sup>2</sup>Muhibili National Hospital, Dar-es-Salaam, Tanzania; <sup>3</sup>Lancet Pathology, Nairobi, Kenya; <sup>4</sup>Department of Histopathology, Royal Blackburn Hospital, Blackburn, UK
- 14.45–15.00 **[O4] Remote Teaching of Histopathology Using Scanned Slides via Skype® Between the UK and Nigeria**  
 © Rotimi<sup>1</sup>; © NO Orah<sup>2</sup>; A Shabaan<sup>3</sup>; AO Daramola<sup>4</sup>; FB Abdulkareem<sup>4</sup>  
<sup>1</sup>St James's University Teaching Hospital, Leeds, UK; <sup>2</sup>Lagos University Teaching Hospital (L.U.T.H.), Idi Araba, Nigeria; <sup>3</sup>Queen Elizabeth Hospital, Birmingham, UK; <sup>4</sup>Lagos University Teaching Hospital, Idi Araba, Nigeria
- 15.00–15.15 **[O5] Development of a Pathology Training Programme in Zambia**  
 © RJ Byers<sup>1</sup>; AJ Merritt<sup>2</sup>; C Marimo<sup>3</sup>; V Mudenda<sup>3</sup>; K Fleming<sup>4</sup>  
<sup>1</sup>Manchester Royal Infirmary, Manchester, UK; <sup>2</sup>Blackburn Royal Hospital, Blackburn, UK; <sup>3</sup>University Teaching Hospital, Lusaka, Zambia; <sup>4</sup>Centre for Global Health, Washington, United States
- 15.15–15.45 **REFRESHMENTS and TRADE EXHIBITION** [Banqueting Suite]

▶ 14.00 – 17.00 — continued

Conference Suite 3

## ORAL PRESENTATIONS

**Breast**

Chair: Prof E Rakha, Nottingham, UK  
Prof AM Hanby, Leeds, UK

- 15.45–16.00 **[O6] The Merits of Reverse Phase Protein Array for Molecular Classification of Breast Cancer**  
 © OH Negm; AA Muftah; MA Aleskandarany; MR Hamed; DAJ Ahmad; CC Nolan; MD Rodriguez; PJ Tighe; IO Ellis; EA Rakha; AR Green  
 University of Nottingham, Nottingham, UK
- 16.00–16.15 **[O7] Vesicular Transporter Proteins in Invasive Breast Cancer: Clinicopathological Relevance of Synaptosomal-Associated Protein-23 (SNAP23)**  
 © SN Sonbul<sup>1</sup>; A Mukherjee<sup>1</sup>; MA Aleskandarany<sup>1</sup>; R Russell<sup>2</sup>; O Rueda<sup>2</sup>; AR Green<sup>1</sup>; CC Nolan<sup>1</sup>; M Diez-Rodriguez<sup>1</sup>; E Provenzano<sup>3</sup>; C Caldas<sup>3</sup>; IO Ellis<sup>1</sup>; EA Rakha<sup>1</sup>  
<sup>1</sup>Department of Pathology, School of Medicine, University of Nottingham, Nottingham, UK; <sup>2</sup>CRUK Cambridge Research Institute, University of Cambridge, Cambridge, UK; <sup>3</sup>Addenbrooke's Hospital, Cambridge Breast Unit, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK
- 16.15–16.30 **[O8] The Prognostic Significance of KRAS-Induced Actin-Interacting Protein (KRAP) Expression in Invasive Breast Cancer**  
 © C Joseph<sup>1</sup>; R Russell<sup>2</sup>; M Craze<sup>1</sup>; C Nolan<sup>1</sup>; E Provenzano<sup>3</sup>; C Caldas<sup>4</sup>; A Green<sup>1</sup>; E Rakha<sup>5</sup>; IO Ellis<sup>5</sup>; A Mukherjee<sup>5</sup>  
<sup>1</sup>Department of Histopathology, School of Medicine, University of Nottingham, Nottingham, UK; <sup>2</sup>CRUK Cambridge Research Institute, Cambridge, UK; <sup>3</sup>Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK; <sup>4</sup>CRUK Cambridge Research Institute, Addenbrooke's Hospital, Cambridge, UK; <sup>5</sup>Department of Histopathology, Nottingham University Hospitals NHS Trust, Nottingham, UK
- 16.30–16.45 **[O9] PALB2 is Downregulated in Sporadic Triple Negative Invasive Breast Cancer and is Associated with Poor Prognosis**  
 © S Gurhan<sup>1</sup>; MA Aleskandarany<sup>1</sup>; CC Nolan<sup>1</sup>; M Diez-Rodriguez<sup>1</sup>; D Caracappa<sup>2</sup>; RD Macmillan<sup>1</sup>; S Madhusudan<sup>1</sup>; IO Ellis<sup>1</sup>; EA Rakha<sup>1</sup>; AR Green<sup>1</sup>  
<sup>1</sup>Nottingham City Hospital, Nottingham, UK; <sup>2</sup>S. Maria della Misericordia Hospital, University of Perugia, Perugia, Italy

▶ 14.00 – 17.00 — *continued*

Conference Suite 3

## ORAL PRESENTATIONS

**Breast** (continued)

- 16.45–17.00 **[O10] Radiological, Histological Features and Outcome of Classical Lobular Carcinoma In Situ with Comedo-Necrosis: A Multi-Institutional Series**  
 © AM Shaaban<sup>1</sup>; N Elgeredly<sup>2</sup>; N Sharma<sup>3</sup>; S Sundararajan<sup>4</sup>; Y Maurice<sup>5</sup>; J Loane<sup>6</sup>; A Manoharan<sup>7</sup>  
<sup>1</sup>Queen Elizabeth Hospital Birmingham, Birmingham, UK; <sup>2</sup>Stockport Foundation Trust, Stockport, UK; <sup>3</sup>St James's University Hospital, Leeds, UK; <sup>4</sup>Royal Stoke University Hospital, Stoke-on-Trent, UK; <sup>5</sup>Wirral University Hospital NHS Foundation Trust, Wirral, UK; <sup>6</sup>Western General Hospital, Edinburgh, UK; <sup>7</sup>The Royal Oldham Hospital, Oldham, UK

## ▶ 14.00 – 17.00

Conference Suite 1

## SYMPOSIUM

**Hepatobiliary Pathology**

Chair: Dr AM Zaitoun, Queen's Medical Centre, Nottingham, UK  
 Dr P Kaye, Nottingham University Hospitals NHS Trust, Nottingham, UK

- 14.00–14.30 **[S17] Genetic Factors and Mechanism Underlying Drug Induced Liver Injury**  
 Prof GP Aithal  
 Nottingham University Hospitals and University of Nottingham, Nottingham, UK
- 14.30–15.00 **[S18] Patterns of Drug-Induced Liver Injury**  
 Prof SG Hubscher  
 University of Birmingham, Birmingham, UK
- 15.00–15.30 **[S19] Liver Disease in the Immunocompromised Patient**  
 Dr SE Davies  
 Cambridge UH NHSFT, Cambridge, UK
- 15.30–15.55 **REFRESHMENTS and TRADE EXHIBITION** [Banqueting Suite]
- 15.55–16.25 **Challenges in Pancreas Pathology**  
 Prof F Campbell  
 Royal Liverpool University Hospital, Liverpool, UK
- 16.25–16.55 **The Role of the Pathologist in the Diagnosis, Management and Prognosis of Pancreatobiliary Neoplasms**  
 Dr AM Zaitoun  
 Nottingham University Hospitals NHS Trust, Nottingham, UK

## ▶ 14.00 – 17.00

Conference Suite 2

## SYMPOSIUM

**Head and Neck Pathology**

Chair: Prof K McLennan, The Leeds Teaching Hospital NHS Trust, Leeds, UK  
 Dr R Allibone, Queen's Medical Centre, Nottingham, UK

- 14.00–14.40 **[S20] PREDICTR Study: Biomarkers in Oro-Pharyngeal Squamous Cell Carcinoma**  
 Dr MC Robinson  
 Newcastle University, Newcastle upon Tyne, UK
- 14.40–15.20 **[S21] Is it Worth Vaccinating Boys Against HPV? — A Pathologist's Perspective**  
 Prof CJL Meijer  
 Dept of Pathology, Vrije University Medical Center, Amsterdam, Netherlands
- 15.20–15.45 **REFRESHMENTS and TRADE EXHIBITION** [Banqueting Suite]
- 15.45–16.20 **The New WHO Classification of Head and Neck Tumours: Principle Changes and New Entities**  
 Dr A Sandison  
 Imperial College London, London, UK
- 16.20–16.55 **Head and Neck 5000 Study – Now Being Analysed**  
 Dr M Pring  
 University of Bristol, Bristol, UK

## ▶ 14.00 – 16.50

Gallery 2 / 3

## UNDERGRADUATE DAY

**Undergraduate Presentations and Prize Presentation**

Chair: Dr RJ Byers, University of Manchester, Manchester, UK  
 Mr C Slater, University of Manchester, Manchester, UK

- 14.00–14.05 **Introduction**  
 Dr RJ Byers  
 University of Manchester, Manchester, UK
- 14.05–14.20 **[P7] Phosphorylated Activating Transcription Factor 2 is Related to Good Prognosis in Invasive Breast Cancer**  
 DA Jerjees; KW Cheng; T Aliyeva; L Gooding; © A Amoah-Duodu; M Diez-Rodriguez; CC Nolan; IO Ellis; AR Green; EA Rakha; MA Aleskandarany  
 Nottingham City Hospital, Nottingham, UK



▶ 14.00 – 16.50 — *continued*

Gallery 2 / 3

**UNDERGRADUATE DAY****Undergraduate Presentations and Prize Presentation** (continued)

- 14.20–14.35 **[P70] Colorectal Cancer Resection and Lymph Node Yield: Predictive Factors Through Specimen Report Analysis**  
 © M Fahmy; B Newell; AJ Mehta; LD Hatter; M Sidapra  
 St George's University London, London, UK
- 14.35–14.50 **[P120] Expression of PD1 in Cutaneous Malignant Melanoma and its Prognostic Significance**  
 © B Sim<sup>1</sup>; S Elsheikh<sup>2</sup>  
<sup>1</sup>School of Medicine, University of Nottingham, Nottingham, UK; <sup>2</sup>Department of Cellular Pathology, Queen's Medical Centre, Nottingham, UK
- 14.50–15.05 **[P30] In situ Quantification of Genomic Instability in Lung Adenocarcinoma: Biomarker Potential and the Biological Implications**  
 © D Kotecha<sup>1</sup>; DA Moore<sup>1</sup>; J Le Quesne<sup>2</sup>  
<sup>1</sup>Department of Cancer Studies, University of Leicester, Leicester, UK; <sup>2</sup>MRC Toxicology Unit, Leicester, UK
- 15.05–15.20 **[P29] Determining the Three Dimensional Architecture of Pulmonary Adenocarcinomas on a Microscopic Scale**  
 © EL Johnstone; DA Moore; N Morone; JPC Le Quesne  
 University of Leicester, Leicester, UK
- 15.20–15.45 **REFRESHMENTS and TRADE EXHIBITION** [Banqueting Suite]
- 15.45–15.50 **2016 Pathological Society Undergraduate Essay Prize Competition Winner Presentation**  
 Presented to Mr M Narajos, Oxford
- 15.50–16.05 **[P47] The Use of MGMT Promoter Methylation Testing in the Management of High-Grade Glioma in South-East Scotland**  
 © K Rakovic<sup>1</sup>; K Walsh<sup>1</sup>; A Torgersen<sup>2</sup>; A Oniscu<sup>1</sup>  
<sup>1</sup>Royal Infirmary of Edinburgh, Edinburgh, UK; <sup>2</sup>Western General Hospital, Edinburgh, UK
- 16.05–16.20 **[P80] Histopathology as the "Gold Standard"? Audit Study of the Certainty of Diagnosis in Duodenal Biopsies Taken to Investigate Patients for Coeliac Disease**  
 © K Donovan; EJ Soilleux  
 Oxford University, Oxford, UK

▶ 14.00 – 16.50 — *continued*

Gallery 2 / 3

- 16.20–16.35 **[P83] Expression of PD-1 and CTLA-4 Ligands in Invasive Bladder Cancer Mouse Models**  
 © M Allam<sup>1</sup>; NF Ismail<sup>1</sup>; R Lightbody<sup>1</sup>; S Fraser<sup>2</sup>; OJ Sansom<sup>3</sup>; T Iwata<sup>1</sup>  
<sup>1</sup>School of Medicine, University of Glasgow, Glasgow, UK; <sup>2</sup>Department of Pathology, Queen Elizabeth University Hospital, Glasgow, UK; <sup>3</sup>Beatson Institute for Cancer Research, Glasgow, UK
- 16.35–16.50 **[P105] Determination of Histological Predictive Parameters for MYC Rearrangement in Diffuse Large B-cell Lymphoma**  
 © K Milne; EJ Soilleux  
 Oxford University, Oxford, UK

▶ 17.00 – 17.50

Conference Theatre

**PUBLIC LECTURE**

Chair: Prof M Ilyas, University of Nottingham, Nottingham, UK

**The 100,000 Genomes Project – Transforming the NHS?**

Dr TA Fowler

Genomic Health England, London, UK

▶ 18.30 – 20.30

Nottingham Castle

**WELCOME RECEPTION  
and OPTIONAL CAVE TOUR**

Buses depart at 18.00

▶ 07.30

Foyer

## REGISTRATION and COFFEE

▶ 08.00 – 18.00

Conference Suite 4

## SLIDE SEMINAR CASE COMPETITION VIEWING

▶ 08.00 – 08.50

Conference Suite 3

## TRAINEES' MEET THE EXPERTS

**Dermatopathology**

(Light breakfast will be provided)

Chair: Dr M Clarke, Brighton Health Care NHS Trust, Brighton, UK

Dr L Wastall, Leeds Teaching Hospitals, Leeds, UK

08.00–08.25 **[S22] Dermatopathology**

Dr W Merchant

*St James's Hospital Leeds, Leeds, UK*08.25–08.50 **[S23] Cutaneous Lymphomas**

Dr A Robson

*IPOLFG, Lisbon, Portugal*

▶ 08.55 – 11.50

Conference Theatre

## SYMPOSIUM

**Gastrointestinal Pathology**

Chair: Prof M Ilyas, University of Nottingham, Nottingham, UK

Prof I Tomlinson, University of Oxford, Oxford, UK

09.00–09.30 **[S24] Neutral Evolution in Colorectal Cancer: How Can We Distinguish Functional from Non-functional Variation?**© Prof A Sottoriva<sup>1</sup>; TA Graham<sup>2</sup>; B Werner<sup>1</sup>; M Williams<sup>2</sup>; C Barnes<sup>3</sup><sup>1</sup>The Institute of Cancer Research, London, UK; <sup>2</sup>Queen Mary University of London, London, UK; <sup>3</sup>UCL, London, UK09.30–10.00 **[S25] The Consensus Molecular Subtypes of Colorectal Cancer**

Prof L Vermeulen

*Academic Medical Center, Amsterdam, UK*10.00–10.30 **[S26] Somatic Evolution of Barrett's / Oesophageal Cancer**

Dr SA McDonald

*Queen Mary, University of London, London, UK*10.30–10.50 **REFRESHMENTS and TRADE EXHIBITION** [Banqueting Suite]▶ 08.55 – 11.50 — *continued*

Conference Theatre

10.50–11.20 **[S27] Molecular Heterogeneity of Gastric Cancer**

Prof HI Grabsch

*Maastricht University Medical Center, Maastricht, Netherlands***GUEST LECTURE – JAPANESE SOCIETY OF PATHOLOGY**11.20–11.50 **[S28] Gastric Adenocarcinoma of Fundic Gland Type – A New Entity**© Prof T Yao<sup>1</sup>; H Ueyama<sup>2</sup><sup>1</sup>Juntendo University Graduate School of Medicine, Tokyo, Japan; <sup>2</sup>Juntendo University School of Medicine, Tokyo, Japan

▶ 08.55 – 12.00

Conference Suite 3

## SYMPOSIUM

**Breast Pathology**

Chair: Prof IO Ellis, University of Nottingham, Nottingham, UK

Prof E Rakha, Nottingham University Hospitals NHS Trust,

Nottingham, UK

09.00–09.30 **[S29] The Role of Immunohistochemistry in Diagnosis in Breast Pathology**

Dr AHS Lee

*Nottingham University Hospitals, Nottingham, UK*09.30–10.00 **[S30] An Update on the Biology, Pathology and Implications of Breast Cancer Risk Lesions**

Prof SE Pinder

*King's College London, London, UK*10.00–10.30 **[S31] An Update on the Molecular Classification of Breast Cancer**

Prof EA Rakha

*University of Nottingham, Nottingham, UK*10.30–10.50 **REFRESHMENTS and TRADE EXHIBITION** [Banqueting Suite]10.50–11.20 **The Role of Myoepithelial Cells in Breast Disease**

Prof LJ Jones

*Queen Mary, University of London, London, UK*11.20–11.50 **THE ROYAL COLLEGE OF PATHOLOGISTS****NEERA PATEL LECTURE**

Introduced by Dr RD Liebmann, Registrar, Royal College of Pathologists

**Contribution of Molecular Techniques to Understanding the Biology of Uncommon Breast Lesions**

Prof JS Reis-Filho

*Memorial Sloan Kettering Cancer Center, New York, USA*

▶ 08.55 – 12.00

Conference Suite 1

## SYMPOSIUM

**Genitourinary Pathology**

Chair: Prof DM Berney, Barts Cancer Institute, Queen Mary University of London, London, UK  
Dr T McCulloch, Nottingham University Hospitals NHS Trust, Nottingham, UK

09.00–09.30 **[S32] Atypical Large Glandular Proliferations of the Prostate**

Dr M Varma  
University Hospital of Wales, Cardiff, UK

09.30–10.00 **[S33] An Introduction to the New Grading System for Prostate Cancer**

Prof DM Berney  
Queen Mary University of London, London, UK

10.00–10.30 **[S34] What the Clinician Wants in Prostatic Biopsy and Prostatectomy Reporting**

Dr TJ Walton  
Nottingham University Hospitals NHS Trust, Nottingham, UK

10.30–10.50 **REFRESHMENTS and TRADE EXHIBITION** [Banqueting Suite]10.50–11.20 **[S35] Pathology and Imaging in Prostate Cancer**

Dr HU Ahmed  
University College London, London, UK

11.20–11.50 **[S36] Prostate Cancer: Molecular and IHC Approaches**

Prof C Magi-Galluzzi  
Cleveland Clinic, Cleveland, Ohio, USA

▶ 12.00 – 12.45

Conference Theatre

**THE PATHOLOGICAL SOCIETY OF GREAT BRITAIN & IRELAND  
CL OAKLEY LECTURE**

Chair: Dr RJ Byers, General Secretary, The Pathological Society;  
University of Manchester, Manchester, UK

**Quantifying Clonal Evolution in the Human Colon**

Dr TA Graham  
Queen Mary University of London, London, UK

▶ 13.00 – 14.00

Banqueting Suite

**LUNCH, TRADE EXHIBITION and POSTER VIEWING**

▶ 14.00 – 17.00

Conference Theatre

## ORAL PRESENTATIONS — 1

**Gastrointestinal; Technical Advances**

Chair: Prof P Quirke, Leeds, UK  
Prof HI Grabsch, Maastricht, Netherlands

14.00–14.15 **[O11] How Close are we to Standardised Extended RAS Gene Mutation Testing? The UK NEQAS Experience**

© SD Richman<sup>1</sup>; J Fairley<sup>2</sup>; R Butler<sup>3</sup>; Z Deans<sup>2</sup>  
<sup>1</sup>Leeds Institute of Cancer and Pathology, Leeds, UK; <sup>2</sup>UK NEQAS for Molecular Genetics, Edinburgh, UK; <sup>3</sup>Cardiff and Vale UHB - Medical Genetics, Cardiff, UK

14.15–14.30 **[O12] Characterisation of Arachidonic Acid Metabolising Enzymes in Colorectal Cancer**

© A Alnabulsi<sup>1</sup>; R Swan<sup>1</sup>; B Cash<sup>2</sup>; A Alnabulsi<sup>2</sup>; GI Murray<sup>1</sup>  
<sup>1</sup>University of Aberdeen, Aberdeen, UK; <sup>2</sup>Vertebrate Antibodies, Aberdeen, UK

14.30–14.45 **[O13] Comparative Analysis of Primary Tumour and Matched Metastasis in Colorectal Cancer Patients; Investigate Genomic, Transcription and Translational Profiles**

© OH Negm<sup>1</sup>; HH Karim<sup>1</sup>; K Manger<sup>2</sup>; J Hassall<sup>1</sup>; W Fadhil<sup>1</sup>; PJ Tighe<sup>3</sup>; M Ilyas<sup>1</sup>  
<sup>1</sup>University of Nottingham, Nottingham, UK; <sup>2</sup>Nottingham University Hospitals NHS Trust, Nottingham, UK; <sup>3</sup>School of Life Sciences, University of Nottingham, Nottingham, UK

14.45–15.00 **[O14] ADAM-17/FHL2 Colocalisation Suggests Interaction and Role of These Proteins in Colorectal Cancer**

L Verset<sup>1</sup>; J Tommelein<sup>2</sup>; C Decaestecker<sup>3</sup>; I Salmon<sup>1</sup>; O De Wever<sup>2</sup>;  
© P Demetter<sup>1</sup>  
<sup>1</sup>Department of Pathology, Erasme University Hospital, Brussels, Belgium; <sup>2</sup>Department of Radiation Oncology and Experimental Cancer Research, UGent, Ghent, Belgium; <sup>3</sup>Digital Image Analysis in Pathology (DIAPATH), CMMI, Gosselies, Belgium

15.00–15.15 **[O15] Short Term Pathology Results from the First World Wide Randomised Trial of Robotic Versus Laparoscopic Resection for Rectal Cancer (ROLARR)**

© NP West<sup>1</sup>; DG Jayne<sup>1</sup>; A Pigazzi<sup>2</sup>; H Marshall<sup>1</sup>; J Croft<sup>1</sup>; N Corrigan<sup>1</sup>;  
J Copeland<sup>1</sup>; T Rautio<sup>3</sup>; N Thomassen<sup>4</sup>; H Tilney<sup>5</sup>; M Gudgeon<sup>5</sup>;  
P Bianchi<sup>6</sup>; JM Brown<sup>1</sup>; P Quirke<sup>1</sup>  
<sup>1</sup>University of Leeds, Leeds, UK; <sup>2</sup>University of California, Irvine, United States; <sup>3</sup>Oulu University Hospital, Oulu, Finland; <sup>4</sup>Aarhus Hospital, Aarhus, Denmark; <sup>5</sup>Frimley Park Hospital, Frimley, UK; <sup>6</sup>Ospedale La Misericordia, Grosseto, Italy

15.15–15.45 **REFRESHMENTS and TRADE EXHIBITION** [Banqueting Suite]

▶ 14.00 – 17.00 — *continued*

Conference Theatre

ORAL PRESENTATIONS — 1 (*continued*)

- 15.45–16.00 **[O16] Parietal Cell, Chief Cell Densities and Intra-gastric Acidity are Reduced in Healthy Volunteers with *H. pylori* Infection Relative to Non-infected Volunteers**  
 © MH Derakhshan<sup>1</sup>; DR Mitchell<sup>1</sup>; AA Wirz<sup>1</sup>; SA Ballantyne<sup>2</sup>; A Weir<sup>2</sup>; KEL McColl<sup>1</sup>; JJ Going<sup>1</sup>  
<sup>1</sup>University of Glasgow, Glasgow, UK; <sup>2</sup>NHS Greater Glasgow & Clyed, Glasgow, UK
- 16.00–16.15 **[O17] Longitudinal Single Cell Clonal Analysis Reveals Evolutionary Stasis and Predetermined Malignant Potential in Non-Dysplastic Barrett's Esophagus**  
 © P Martinez<sup>1</sup>; MR Timmer<sup>2</sup>; CT Lau<sup>2</sup>; CC Maley<sup>3</sup>; TA Graham<sup>1</sup>; KK Krishnadath<sup>2</sup>  
<sup>1</sup>Barts Cancer Institute, London, UK; <sup>2</sup>Amsterdam Medical Centrum, Amsterdam, Netherlands; <sup>3</sup>Arizona State University, Phoenix, USA
- 16.15–16.30 **[O18] The MERCURY II Study: Prospective Validation of a Low Rectal Cancer Assessment System Using Magnetic Resonance Imaging, and Development of a Local Recurrence Risk Stratification Model**  
 NJ Battersby<sup>1</sup>; P How<sup>1</sup>; BJ Moran<sup>2</sup>; S Stelzner<sup>3</sup>; © NP West<sup>4</sup>; G Branagan<sup>5</sup>; J Strassburg<sup>6</sup>; P Quirke<sup>4</sup>; P Tekkis<sup>7</sup>; BG Pedersen<sup>8</sup>; A Gudgeon<sup>9</sup>; RJ Heald<sup>10</sup>; G Brown<sup>11</sup>  
<sup>1</sup>Pelican Cancer Foundation, Basingstoke, UK; <sup>2</sup>North Hampshire Hospital, Basingstoke, UK; <sup>3</sup>Dresden-Friedrichstadt General Hospital, Dresden, Germany; <sup>4</sup>University of Leeds, Leeds, UK; <sup>5</sup>Salisbury District Hospital, Salisbury, UK; <sup>6</sup>Vivantes im Friedrichshain, Berlin, Germany; <sup>7</sup>The Royal Marsden NHS Foundation Trust, London, UK; <sup>8</sup>Aarhus University Hospital, Aarhus, Denmark; <sup>9</sup>Frimley Park Hospital, Frimley, UK; <sup>10</sup>Pelican Cancer Foundation, Basingstoke, UK; <sup>11</sup>The Royal Marsden Hospital, Sutton, UK
- 16.30–16.45 **[O19] Exploring the Suitability and Stability of Guaiac Faecal Occult Blood Test Cards to Isolate Microbial DNA for 16srRNA Sequencing**  
 © M Taylor<sup>1</sup>; HM Wood<sup>1</sup>; S Halloran<sup>2</sup>; P Quirke<sup>1</sup>  
<sup>1</sup>Leeds Institute of Cancer and Pathology, Leeds, UK; <sup>2</sup>University of Surrey, Guildford, UK
- 16.00–17.00 **[O20] Digital Microscopy is Non-inferior to Optical Microscopy in the Diagnosis of Dysplasia in Barrett's Oesophagus: A Validation Study**  
 © C Marchessoux<sup>1</sup>; PV Kaye<sup>2</sup>; A Mukherjee<sup>2</sup>; S Paine<sup>2</sup>; A Haider<sup>2</sup>; M Ilyas<sup>3</sup>  
<sup>1</sup>Barco, Kortrijk, Belgium; <sup>2</sup>Nottingham University Hospitals, Nottingham, UK; <sup>3</sup>University of Nottingham, Nottingham, UK

▶ 14.00 – 17.00

Conference Suite 3

## ORAL PRESENTATIONS — 2

**Breast; Technical Advances**Chair: Prof LJ Jones, London, UK  
Prof SE Pinder, London, UK

- 14.00–14.15 **[O21] Ankyrin 3 Protein may Influence DNA-Damage Response Pathways and the Immune Response in Invasive Breast Carcinoma**  
 SN Sonbul; © M Pigerá; A Mukherjee; MA Aleskandarany; AR Green; M Diez-Rodriguez; C Joseph; CC Nolan; IO Ellis; EA Rakha  
 Department of Pathology, School of Medicine, University of Nottingham, Nottingham, UK
- 14.15–14.30 **[O22] Further Evidence to Support that Oestrogen Receptor Expression in Breast Cancer is Bimodal**  
 © AA Muftah<sup>1</sup>; MA Aleskandarany<sup>1</sup>; SN Sonbul<sup>1</sup>; CC Nolan<sup>1</sup>; M Diez Rodriguez<sup>1</sup>; C Caldas<sup>2</sup>; IO Ellis<sup>1</sup>; AR Green<sup>1</sup>; EA Rakha<sup>1</sup>  
<sup>1</sup>University of Nottingham, School of Medicine, City Hospital Campus, Division of Cancer and Stem Cells, Nottingham, UK; <sup>2</sup>Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK
- 14.30–14.45 **[O23] Exploring Molecular Portraits Defining Low Grade in Breast Cancer**  
 © A Mukherjee<sup>1</sup>; R Russell<sup>2</sup>; OM Rueda<sup>2</sup>; S Hamarsheh<sup>3</sup>; C Caldas<sup>4</sup>; E Provenzano<sup>5</sup>; IO Ellis<sup>3</sup>  
<sup>1</sup>Department of Histopathology, Nottingham University Hospitals NHS Trust, Nottingham, UK; <sup>2</sup>CRUK Cambridge Research Institute, Cambridge, UK; <sup>3</sup>Department of Histopathology, School of Medicine, University of Nottingham, Nottingham, UK; <sup>4</sup>CRUK Cambridge Research Institute, Addenbrooke's Hospital, Cambridge, UK; <sup>5</sup>Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK
- 14.45–15.00 **[O24] Nostrin as a Marker Related to Low Grade and Better Prognosis in Breast Cancer**  
 S Hamarsheh<sup>1</sup>; M Craze<sup>1</sup>; C Joseph<sup>1</sup>; E Provenzano<sup>2</sup>; R Russell<sup>3</sup>; C Caldas<sup>4</sup>; AR Green<sup>1</sup>; E Rakha<sup>5</sup>; IO Ellis<sup>5</sup>; © A Mukherjee<sup>5</sup>  
<sup>1</sup>Department of Histopathology, School of Medicine, University of Nottingham, Nottingham, UK; <sup>2</sup>Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK; <sup>3</sup>CRUK Cambridge Research Institute, Cambridge, UK; <sup>4</sup>CRUK Cambridge Research Institute, Addenbrooke's Hospital, Cambridge, UK; <sup>5</sup>Department of Histopathology, Nottingham University Hospitals NHS Trust, Nottingham, UK
- 15.00–15.15 **[O25] Phenotypic and Immunophenotypic Characterisation of Recurrent Breast Cancer**  
 © DY Al-Bazz; MA Aleskandarany; CC Nolan; M Diez-Rodriguez; IO Ellis; EA Rakha; AR Green  
 University of Nottingham, Nottingham, UK
- 15.15–15.45 **REFRESHMENTS and TRADE EXHIBITION [Banqueting Suite]**

**ORAL PRESENTATIONS — 2** (*continued*)

- 15.45–16.00 **[O26] Research Studies and Level of Diagnostic Concordance in Breast Pathology: Lessons from the UK EQA Scheme**  
 EA Rakha<sup>1</sup>; © MAH Ahmed<sup>1</sup>; AH Lee<sup>2</sup>; Z Hodi<sup>2</sup>; M Aleskandarany<sup>1</sup>; D Coleman<sup>3</sup>; RA Bennett<sup>4</sup>; C Hawkes<sup>1</sup>; IO Ellis<sup>1</sup>  
<sup>1</sup>Division of Cancer and Stem Cells, School of Medicine, The University of Nottingham, Department of Histopathology, Nottingham, UK; <sup>2</sup>Department of Histopathology, Nottingham University Hospitals, City Hospital Campus, Hucknall Road, Nottingham, UK; <sup>3</sup>Cancer Screening Evaluation Unit, Institute of Cancer Research, Sutton, Surrey, UK; <sup>4</sup>Nottingham University Hospitals NHS Trust, Nottingham, UK
- 16.00–16.15 **[O27] Expression of CUL4A in invasive Breast Cancer: a Biomarker of Good Prognosis Related to Tumour Differentiation**  
 © MA Aleskandarany<sup>1</sup>; R Surridge<sup>1</sup>; S Sonbul<sup>1</sup>; A Elmouna<sup>2</sup>; I Ashankyty<sup>2</sup>; E Nuglozeh<sup>2</sup>; MF Fazaludeen<sup>2</sup>; CC Nolan<sup>1</sup>; M Diez-Rodriguez<sup>1</sup>; IO Ellis<sup>1</sup>; AR Green<sup>1</sup>; EA Rakha<sup>1</sup>  
<sup>1</sup>Nottingham City Hospital, Nottingham, UK; <sup>2</sup>Molecular Diagnostics and Personalised Therapeutics Unit, University of Ha'il, Ha'il, Saudi Arabia
- 16.15–16.30 **[O28] Multiple Coagulation Factor Deficiency Protein-2 (MCFD2) as a Potential Prognostic Germ Cell Marker in Invasive Breast Carcinoma: a Transcriptome-Driven Study**  
 © SN Sonbul<sup>1</sup>; A Mukherjee<sup>1</sup>; R Russell<sup>2</sup>; OM Rueda<sup>2</sup>; MA Aleskandarany<sup>1</sup>; AR Green<sup>1</sup>; CC Nolan<sup>1</sup>; M Diez-Rodriguez<sup>1</sup>; E Provenzano<sup>3</sup>; C Caldas<sup>3</sup>; IO Ellis<sup>1</sup>; EA Rakha<sup>1</sup>  
<sup>1</sup>Department of Pathology, School of Medicine, University of Nottingham, Nottingham, UK; <sup>2</sup>CRUK Cambridge Research Institute, University of Cambridge, Cambridge, UK; <sup>3</sup>Addenbrooke's Hospital, Cambridge Breast Unit, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK
- 16.30–16.45 **[O29] Diagnosing Breast Fibroepithelial Lesions: How Accurate are Core Biopsy Categories in Assessing for Phyllodes Tumour and How Well do Fibroepithelial Diagnoses in Excisions Predict Their Behaviour?**  
 © WJ Dalleywater<sup>1</sup>; MM Al-kaabi<sup>2</sup>; J White<sup>3</sup>; N Khirwadkar<sup>3</sup>; Y Mir<sup>3</sup>; E Rakha<sup>4</sup>  
<sup>1</sup>Leicester Royal Infirmary, Leicester, UK; <sup>2</sup>Nottingham University Hospitals, Nottingham, UK; <sup>3</sup>Royal Liverpool and Broadgreen Hospitals, Liverpool, UK; <sup>4</sup>University of Nottingham, Nottingham, UK
- 16.00–17.00 **[O30] Intra-Operative Assessment of Sentinel Lymph Nodes by Selective-Scanning Raman Spectroscopy**  
 © DW Shipp<sup>1</sup>; EA Rakha<sup>2</sup>; I Notinger<sup>1</sup>  
<sup>1</sup>University of Nottingham, Nottingham, UK; <sup>2</sup>Nottingham University Hospitals NHS Trust, Nottingham, UK

**ORAL PRESENTATIONS — 3**

**Genitourinary; Cellular/Molecular; Technical Advances; Haematopathology**

Chair: Dr RJ Byers, Manchester, UK  
 Dr EJ Soilleux, Oxford, UK

- 14.00–14.15 **[O31] The Significance of Reporting Perineural Invasion in 988 Conservatively Treated Prostate Cancer Patients with Long Term Outcome**  
 © V Parameshwaran<sup>1</sup>; BV North<sup>1</sup>; H Møller<sup>2</sup>; P Scardino<sup>3</sup>; J Cuzick<sup>1</sup>; L Beltran<sup>1</sup>; DM Berney<sup>1</sup>  
<sup>1</sup>Queen Mary University of London, London, UK; <sup>2</sup>Kings College University of London, London, UK; <sup>3</sup>Memorial Sloane Kettering Cancer Centre, New York City, USA
- 14.15–14.30 **[O32] Vascular Insulin-Like Growth Factor Receptor Type 2 (IGF2R) Expression is Upregulated in Malignant Tumours**  
 © AL Trépant<sup>1</sup>; N D'Haene<sup>1</sup>; J Allard<sup>2</sup>; YR Van Eycke<sup>2</sup>; C Decaestecker<sup>2</sup>; I Salmon<sup>1</sup>; P Demetter<sup>1</sup>  
<sup>1</sup>Department of Pathology, Erasme University Hospital, Brussels, Belgium; <sup>2</sup>Digital Image Analysis in Pathology (DIAPATH), CMMI, Gosselies, Belgium
- 14.30–14.45 **[O33] Digital PCR Analysis of Circulating Tumour DNA in a Broad Cohort of Sarcoma Patients**  
 © A Gutteridge<sup>1</sup>; VM Rathbone<sup>1</sup>; R Gibbons<sup>2</sup>; F Amary<sup>2</sup>; N Archard<sup>1</sup>; K Davies<sup>1</sup>; J Brown<sup>1</sup>; M Jorgensen<sup>1</sup>; M Gupta<sup>1</sup>; AM Flanagan<sup>1</sup>; T Forshew<sup>1</sup>  
<sup>1</sup>University College London – Cancer Institute, London, UK; <sup>2</sup>Royal National Orthopaedic Hospital NHS Trust (Histopathology), Stanmore, UK
- 14.45–15.00 **[O34] Breaking the Ice: Digital Pathology for Remote Frozen Section Diagnosis — A Two-Year, Single-Centre Experience of 267 Cases**  
 © J Griffin; P Kitsanta; SK Suvarna; B Perunovic; J Bury  
 Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
- 15.00–15.15 **[O35] Demonstration of mRNA Light Chain Restriction in Follicular Lymphomas Using Ultrasensitive In Situ Hybridisation**  
 © A Warford; M Rahman; D Ribeiro  
 University of Westminster, London, UK
- 15.15–15.45 **REFRESHMENTS and TRADE EXHIBITION** [Banqueting Suite]
- 15.45–16.00 **[O36] Evaluation of Relative Sensitivities and Specificities of BRAF Mutation Detection Methodologies, Using the Paradigm of Hairy Cell Leukaemia**  
 © B Cardus; RT Colling; EJ Soilleux; A Hamblin  
 Oxford University, Oxford, UK

▶ 14.00 – 17.00 — *continued*

Conference Suite 3

**ORAL PRESENTATIONS — 3 (continued)**

- 16.00–16.15 **[O37] *Loss of Bone Marrow Mesenchymal Stem Cells in Myeloproliferative Neoplasms as an Indicator of Niche Dysregulation***  
 © E Bishop; A Mead; EJ Soilleux  
*Oxford University, Oxford, UK*
- 16.15–16.30 **[O38] *Ipilimumab Induced Colitis: Is the Epstein Barr Virus (EBV) Implicated?***  
 © MR Pugh<sup>1</sup>; M Morgan<sup>2</sup>; SD Dojcinov<sup>1</sup>  
<sup>1</sup>All Wales Lymphoma Panel - University Hospital of Wales, Cardiff, UK; <sup>2</sup>University Hospital of Wales, Cardiff, UK
- 16.30–16.45 **[O39] *Evaluation of Pro-Survival Signalling Pathways as Novel Therapeutic Targets in Chronic Lymphocytic Leukaemia***  
 © D Kluczna; S Jayne; M Vogler; MJS Dyer; S Macip  
*University of Leicester, Leicester, UK*
- 16.00–17.00 **[O40] *Extending the Concept of Monotypia to T-cells: Use of T Cell-specific RNA in Situ Hybridisation as a Novel Test to Distinguish Malignant (Lymphomatous) and Benign (Inflammatory) T Cell Infiltrates***  
 © EJ Soilleux; M Salimi; T Hassanali; G Ogg  
*Oxford University, Oxford, UK*

▶ 09.00 – 17.00

Gallery 1

**SYMPOSIUM**

***The AIDPATH Project: Her2 Automated Scoring Contest***

For programme details visit: [www.path.org.uk](http://www.path.org.uk)

▶ 17.00 – 18.30

Banqueting Suite

**POSTER VIEWING, CHAIRMAN'S ROUNDS and REFRESHMENTS**

GROUP - CATEGORY	POSTER NUMBER	CHAIR
1 – Autopsy/Forensic	P1–P4	Dr EW Benbow, Manchester; Prof ISD Roberts, Oxford
2 – Breast	P5–P27	Prof AM Hanby, Leeds; Prof E Rakha, Nottingham
3 – Cardiovascular/Pulmonary	P28–P34	Dr I Soomro, Nottingham
4 – Cellular/Molecular Experimental Tumour Pathology	P36–P48 P50–P53 *	Prof AM Flanagan, London; Prof M Ilyas, Nottingham
5 – Education and Audit	P54–P58	Prof SS Cross, Sheffield
6 – Endocrine Head and Neck	P59–P63 P64–P67	Prof G Thomas, Southampton; Dr M Khan, Nottingham
7 – Gastrointestinal	P69–P82 *	Prof RFT McMahon, Manchester; Dr AM Zaitoun, Nottingham
8 – Genitourinary Renal	P83–P89 P90–P91	Prof DM Berney, London; Prof S Fleming, Dundee
9 – Gynaecological	P92–P102	Prof MJ Arends, Edinburgh; Prof CS Herrington, Edinburgh
10 – Haematopathology	P103–P106	Dr RJ Byers, Manchester; Dr EJ Soilleux, Oxford
11 – Hepatobiliary/Pancreas	P107–P112	Prof KP West, Leicester
12 – Neuropathology/Ophthalmic	P113–P114	Dr S Paine, Nottingham
13 – Osteoarticular/Soft Tissue Skin	P115–P116 P117–P125	Dr MF Amary, London; Prof AJ Freemont, Manchester
14 – Technical Advances	P126–P130	Prof GI Murray, Aberdeen

\* P35, P49, P68, P71, P75 have been withdrawn

▶ 07.30

Foyer

**REGISTRATION and COFFEE**

▶ 08.00 – 18.00

Conference Suite 4

**SLIDE SEMINAR CASE COMPETITION VIEWING**

▶ 08.00 – 09.00

Conference Suite 1

**TRAINEES' MEET THE EXPERTS*****GI-Sessile Serrated Lesions***

Chair: Dr G Petts, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK  
 Dr J Sampson, Royal Victoria Infirmary, Newcastle upon Tyne, UK

08.00–08.30 Prof GT Williams  
*University of Cardiff, Cardiff, UK*

08.30–09.00 Dr AC Bateman  
*Southampton University Hospitals NHS Trust, Southampton, UK*

▶ 08.55 – 12.00

Conference Theatre

**SYMPOSIUM*****Mechanisms of Disease: Cutting Edge Topics***

Chair: Prof JS Reis-Filho, Memorial Sloan-Kettering Cancer Center, New York, USA;  
 Dr A Shams-Neteri, University of Nottingham, Nottingham, UK

09.00–09.30 ***Circulating Tumour DNA***  
 Prof J Shaw  
*University of Leicester, Leicester, UK*

09.30–10.00 **[S37] *Cancer Immunotherapy***  
 Prof LG Durrant  
*University of Nottingham, Nottingham, UK*

10.00–10.30 ***Pros and Cons in Pathological Angiogenesis: Why Stopping Blood Vessels Growing is Harder in Some Pathologies than Others***  
 Prof D Bates  
*University of Nottingham, Nottingham, UK*

10.30–11.00 **REFRESHMENTS and TRADE EXHIBITION** [Banqueting Suite]

▶ 08.55 – 12.00 — *continued*

Conference Theatre

11.00–11.30 **[S38] *Viral Oncogenesis and Hepatocellular Carcinoma***  
 Prof WL Irving  
*University of Nottingham, Nottingham, UK*

11.30–12.00 ***Targeting DNA Repair for Personalisation of Breast Cancer Therapy***  
 Dr M Srinivasan  
*University of Nottingham, Nottingham, UK*

▶ 09.00 – 12.00

Conference Suite 1

**SYMPOSIUM*****Musculoskeletal Pathology***

Chair: Prof AM Flanagan, Royal National Orthopaedic Hospital, London, UK  
 Dr T McCulloch, Nottingham University Hospitals NHS Trust, Nottingham, UK

09.00–09.30 **[S39] *GIST: An Expanding Molecular Landscape Driving a Molecular Diagnostic Service – What is New and Relevant***  
 © Dr P Tanriere; B O'Sullivan; M Smith; F Hughes; C Swift; O Cain; N Deshmukh  
*Queen Elizabeth Hospital, Birmingham, UK*

09.30–10.00 **[S40] *Is There a Role for Genetics in the Diagnosis of Undifferentiated Sarcomas?***  
 Dr N Pillay  
*UCL Cancer Institute, London, UK*

10.00–10.30 **[S41] *Molecular Pathology of Bone Tumours – Getting More Accurate Diagnostic, Prognostic and Predictive Information***  
 Dr MF Amary  
*RNOH, London, UK*

10.30–11.00 **REFRESHMENTS and TRADE EXHIBITION** [Banqueting Suite]

11.00–11.30 **[S42] *Stem Cells and Lineage Commitment in Bone Tumours***  
 Dr AE Grigoriadis  
*King's College London, London, UK*

11.30–12.00 **[S43] *The Expanding Family of Ewing's and Related Tumours***  
 Dr F Puls  
*Sahlgrenska University Hospital, Gothenburg, Sweden*

▶ 09.30 – 17.00

Gallery 2 / 3

**BRITISH LYMPHOMA PATHOLOGY GROUP (BLPG) MEETING**For programme details visit: [www.path.org.uk](http://www.path.org.uk)

▶ 08.25 – 12.30

Conference Suite 2

**SYMPOSIUM****Renal Pathology**Chair: Prof ISD Roberts, John Radcliffe University Hospital, Oxford, UK  
Prof M Sheaff, Barts and the London NHS Trust, London, UK08.30–08.42 ***I learned something new from that case***Dr C Roufosse  
*Imperial College London, London, UK*08.42–08.54 ***I learned something new from that case***Dr NS Brearley  
*Queen Alexander Hospital, Portsmouth, UK*08.54–09.06 ***I learned something new from that case***Dr K Wood  
*Newcastle University, Newcastle upon Tyne, UK*09.06–09.18 ***I learned something new from that case***Dr R Perera  
*Guys and St Thomas's Hospital, London, UK*09.18–09.30 **[O41] Clinical Value of Subclassification of Focal Segmental Glomerulosclerosis in IgA Nephropathy**SS Bellur<sup>1</sup>; F Lepeyre<sup>2</sup>; O Vorobyeva<sup>1</sup>; S Troyanov<sup>2</sup>; HT Cook<sup>3</sup>;  
© Prof ISD Roberts<sup>1</sup><sup>1</sup>Oxford University Hospitals, Oxford, UK;<sup>2</sup>Hôpital du Sacré-Coeur de Montréal, Montréal, Canada; <sup>3</sup>Imperial College, London, UK09.30–10.00 **Autosomal Dominant Tubulointerstitial Kidney Disease**Prof HT Cook  
*Imperial College London, London, UK*10.00–10.30 **Banff 2015 Report**Dr C Roufosse  
*Imperial College London, London, UK*10.30–10.50 **REFRESHMENTS and TRADE EXHIBITION** [Banqueting Suite]10.50–11.10 **RCPATH / Renal Registry Issues**Prof M Sheaff  
*Barts Health NHS Trust, London, UK*▶ 08.25 – 12.30 — *continued*

Conference Suite 2

11.10–12.00 **Renal EQA**Prof ISD Roberts  
*John Radcliffe Hospital, Oxford, UK*12.00–12.30 **Renal Transplant EQA**Dr D Neil  
*Queen Elizabeth Hospital, Birmingham, UK*

▶ 12.00 – 13.00

Atrium

**TRAINEES' NETWORKING LUNCH**

▶ 12.00 – 14.00

Banqueting Suite

**LUNCH, TRADE EXHIBITION and POSTER VIEWING**

▶ 13.00 – 14.00

Gallery 1

**THE PATHOLOGICAL SOCIETY OF GREAT BRITAIN & IRELAND ANNUAL GENERAL MEETING**

(Agendas will be sent to Members)

▶ 13.30 – 16.00

Conference Suite 2

**ASSOCIATION OF CLINICAL ELECTRON MICROSCOPISTS (ACEM) MEETING**For programme details visit: [www.path.org.uk](http://www.path.org.uk)

▶ 14.00 – 16.30

Conference Theatre

**PLENARY ORAL PRESENTATIONS**Chair: Prof AM Flanagan, London, UK  
Prof ISD Roberts, Oxford, UK14.00–14.15 **[PL1] Molecular Mediators of Mammographic Density**© A Ironside; J Gomm; L Haywood; I Goulding; J Wang; A Guerra;  
C Chelala; JL Jones  
*Barts Cancer Institute, London, UK*



▶ 14.00 – 16.30 — *continued*

Conference Theatre

PLENARY ORAL PRESENTATIONS *(continued)*

- 14.15–14.30 **[PL2] Exome Sequencing Identifies MSS51 Mitochondrial Translational Activator as a Putative Metastasis Associated Gene in Invasive Breast Carcinoma**  
 MA Aleskandarany<sup>1</sup>; © M Diez-Rodriguez<sup>1</sup>; E Nuglozeh<sup>2</sup>; A Elmouna<sup>2</sup>; MF Fazaludeen<sup>2</sup>; I Ashankyty<sup>2</sup>; S mian<sup>2</sup>; CC Nolan<sup>1</sup>; IO Ellis<sup>1</sup>; AR Green<sup>1</sup>; EA Rakha<sup>1</sup>  
<sup>1</sup>Nottingham City Hospital, Nottingham, UK; <sup>2</sup>Molecular Diagnostics and Personalised Therapeutics Unit, University of Ha'il, Ha'il, Saudi Arabia
- 14.30–14.45 **[PL3] Histological and Genomic Markers of the Switch from In Situ to Invasive Behaviour in Early Lung Adenocarcinoma**  
 © DA Moore<sup>1</sup>; A Crate<sup>1</sup>; G Wilson<sup>2</sup>; JPC Le Quesne<sup>1</sup>  
<sup>1</sup>University of Leicester, Leicester, UK; <sup>2</sup>Crick Institute, London, UK
- 14.45–15.00 **[PL4] UCA1 Overexpression is a New Independent Prognostic Marker in Bladder Cancer Associated with Increased Patient Survival**  
 © L Lebrun<sup>1</sup>; D Milowich<sup>1</sup>; M Le Mercier<sup>1</sup>; J Allard<sup>2</sup>; YR Van Eycke<sup>2</sup>; T Roumeguere<sup>3</sup>; C Decaestecker<sup>4</sup>; I Salmon<sup>1</sup>; S Rorive<sup>1</sup>  
<sup>1</sup>Department of Pathology, Erasme University Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium; <sup>2</sup>DIAPath, Center for Microscopy and Molecular Imaging (CMMI), Académie Universitaire Wallonie-Bruxelles, Gosselies, Belgium; <sup>3</sup>Department of Urology, Erasme University Hospital, Université libre de Bruxelles (ULB), Brussels, Belgium; <sup>4</sup>Laboratories of Image, Signal processing and Acoustics (LISA), Brussels School of Engineering/Ecole Polytechnique de Bruxelles, Brussels, Belgium
- 15.00–15.30 **REFRESHMENTS and TRADE EXHIBITION** [Banqueting Suite]
- 15.30–15.45 **[PL5] Algorithm for Assessment and Prognostic Significance of MYC and BCL2 Expression and Rearrangements in Diffuse Large B-cell Lymphoma (DLBCL) — All Wales Lymphoma Panel Study**  
 © MR Pugh; A Joshi; RL Attanoos; SD Dojcinov  
 All Wales Lymphoma Panel, University Hospital of Wales, Cardiff, UK
- 15.45–16.00 **[PL6] Investigating the Mechanisms Underlying Oligodendrocyte Dysfunction in C9ORF72 ALS**  
 © A Lorente Pons; PJ Shaw; PG Ince; J Cooper-Knock; A Ramachandran; J Kirby; JR Highley; JD Wood  
 Sheffield Institute for Translational Neuroscience (SITraN), Sheffield, UK
- 16.00–16.15 **[PL7] Cten Knockout Using CRISPR/Cas9 Abrogates Cell Migration and Invasion in Colorectal Cancer Cell Lines**  
 © H Thorpe; A Asiri; H Otifi; M Ilyas  
 University of Nottingham, Nottingham, UK

▶ 14.00 – 16.30 — *continued*

Conference Theatre

- 16.15–16.30 **[PL8] An In-Depth Examination of Genomic Heterogeneity in Disseminated Colorectal Cancer**  
 © TG Palmer; HM Wood; M Taylor; W Fateen; IM Carr; P Chambers; P Quirke  
 University of Leeds, Leeds, UK

## ▶ 16.45 – 17.30

Conference Theatre

**THE PATHOLOGICAL SOCIETY OF GREAT BRITAIN & IRELAND  
 DONIACH LECTURE**

Chair: Prof P Quirke, President, The Pathological Society; University of Leeds, Leeds, UK

**Looking at Breast Cancer**

 Prof IO Ellis  
 University of Nottingham, Nottingham, UK

## ▶ 19.00 – 23.00

Banqueting Suite

**CONFERENCE DINNER  
 including Dodgems and Musical Entertainment**

▶ 08.00

Foyer

**REGISTRATION and COFFEE**

▶ 09.00 – 17.00

Gallery 1

**UK CARDIAC PATHOLOGY NETWORK MEETING**For programme details visit: [www.path.org.uk](http://www.path.org.uk)

▶ 09.00 – 14.45

Gallery 2 / 3

**BRITISH LYMPHOMA PATHOLOGY GROUP (BLPG) MEETING**For programme details visit: [www.path.org.uk](http://www.path.org.uk)

▶ 08.30 – 10.00

Conference Suite 4

**TRAINEES' SLIDE SEMINAR DISCUSSION**Chair: Dr NM Orsi, St James's University Hospital, Leeds, UK  
Dr E Short, Cardiff University, Cardiff, UK

08.30–08.40

**Case 1**Dr K Moutasim  
*University of Southampton, Southampton, UK*

08.40–08.50

**Case 2**Dr K Allen  
*Leeds Teaching Hospitals NHS Trust, Leeds, UK*

08.50–09.00

**Case 3**Dr M Clarke  
*Brighton Healthcare NHS Trust, Royal Sussex County Hospital, Brighton, UK*

09.00–09.10

**Case 4**Dr O Dotsenko  
*Royal Hallamshire Hospital, Sheffield, UK*

09.10–09.20

**Case 5**Dr G Petts  
*Central Manchester University Hospitals NHS Foundation Trust, Royal Manchester Children's Hospital, Manchester, UK*

09.20–09.30

**Case 6**Dr J Sampson  
*Royal Victoria Infirmary, Newcastle upon Tyne, UK*▶ 08.30 – 10.00 — *continued*

Conference Suite 4

09.30–09.40

**Case Competition Winner — Trainee**

Dr R Colling, Oxford

▶ 09.55 – 16.30

Conference Suite 3

The Royal College of Pathologists  
Pathology: the science behind the cure**SYMPOSIUM — In association with the Royal College of Pathologists  
Molecular Pathology: Transformative Technologies**Chair: Prof M Ilyas, University of Nottingham, Nottingham UK  
Prof W Irving, University of Nottingham, Nottingham UK

10.00–10.30

**[S45] The Pathologist and the 100K Genome Project**Dr M Jimenez-Linan  
*Cambridge University Hospital, Cambridge, UK*

10.30–11.00

**[S46] Principles of Next Generation Sequencing**Dr A Sharif  
*East Midlands Regional Molecular Genetics Laboratory, Nottingham, UK*

11.00–11.30

**REFRESHMENTS [Atrium]**

11.30–12.00

**[S47] Next Generation Sequencing — Applications**Dr XM Fernandez  
*Thermo Fisher Scientific, Paisley, UK*

12.00–12.30

**[S48] SMRT® Technology – A Paradigm Shift in Sequencing**Dr S Picton  
*Pacific Biosciences, Menlo Park, USA*

12.30–13.30

**LUNCH [Atrium]**

13.30–14.00

**Imaging Mass Spectrometry**Prof Z Takats  
*Imperial College London, London, UK*

14.00–14.30

**[S49] The Use of Proteomics in Diagnostics: Liver Fibrosis Biomarkers**© Dr B Gangadharan; A Kumar; E Barnes; P Klenerman; RA Dwek; N Zitzmann  
*University of Oxford, Oxford, UK*

▶ 09.55 – 16.30 — *continued*

Conference Suite 3

**SYMPOSIUM** — In association with the Royal College of Pathologists  
***Molecular Pathology: Transformative Technologies***  
*(continued)*

14.30–15.00 ***Breathomics – the New Molecular Pathology?***

Prof PS Monks  
*University of Leicester, Leicester, UK*

15.00–15.30 **REFRESHMENTS** [Atrium]

15.30–16.00 ***Early Cancer Detection using Tumour Specific Autoantibodies: the Signal has been there all along***

Prof H Sewell  
*University of Nottingham, Nottingham, UK*

16.00–16.30 **[S50] *Metabolomics: Shedding Light on Human Health and Diseases***

J Wood<sup>1</sup>; A Lourdasamy<sup>1</sup>; J Ward<sup>1</sup>; D Barrett<sup>2</sup>; R Rahman<sup>1</sup>; © Dr DH Kim<sup>2</sup>  
<sup>1</sup>*Children's Brain Tumour Research Centre, School of Medicine, University of Nottingham, Nottingham, UK;* <sup>2</sup>*Centre for Analytical Bioscience, School of Pharmacy, University of Nottingham, Nottingham, UK*

*End of Conference*

**ABSTRACT REVIEWERS**

Dr MF Amary, London

Prof MJ Arends, Edinburgh

Dr C Bacon, Newcastle-upon-Tyne

Dr EW Benbow, Manchester

Prof DM Berney, London

Dr T Brenn, Skin

Dr L Browning, Oxford

Dr L Burke, Cork

Prof SS Cross, Sheffield

Dr J Dormer, Leicester

Prof M-Q Du, Cambridge

Prof RM Feakins, London

Prof S Fleming, Dundee

Prof AJ Freemont, Manchester

Dr TR Helliwell, Liverpool

Prof CS Herrington, Edinburgh

Prof S Hubscher, Birmingham

Prof M Ilyas, Nottingham

Dr M Khan, Nottingham

Dr S Manek, Oxford

Dr S Martin, Nottingham

Prof RFT McMahon, Manchester

Prof GI Murray, Aberdeen

Prof AG Nicholson, London

Dr M Osborn, London

Dr S Paine, Nottingham

Dr N Pillay, London

Dr D Poller, Portsmouth

Dr CM Quinn, Dublin

Prof E Rakha, Nottingham

Dr G Saldanha, Leicester

Prof G Thomas, Southampton

Dr D Treanor, Leeds

Prof P van der Valk, Amsterdam

Dr A Warren, Cambridge

Dr KP West, Leicester

**PRESENTERS INDEX**

Presenter's name followed by abstract number

<b>A</b>	<b>D</b>	<b>H</b>
Adams, DJ..... S16	Dalleywater, WJ..... O29, P85	Hadjimichael, EH..... P117
Ahmed, HU..... S35	Dallmann, A..... P86	Halas, RA..... P116
Ahmed, MAH..... O26	Das, M..... P45	Hamilton, J..... P118
Aithal, GP..... S17	Davie, MM..... P88	Hanby, AM..... S8
Akpenyi, O..... P84	Davies, SE..... S19	Harries, LJ..... P28
Albanghali, MA..... P5	Derakhshan, MH..... O16	Haynes, HR..... P55, P113
Al-Bazz, DY..... O25	Diez-Rodriguez, M..... PL2	Hayward, M..... P23
Aleskandarany, MA..... O27	Demetter P..... O14	Helin, HK..... P56
Aliyeva, T..... P15	Dodwell, D..... S8	Herrington, CS..... S2
Al-kaabi, MM..... P92	Donovan, K..... P80	Horne, J..... P74
Allam, M..... P83	Doorbar, J..... S3, S15	Hubscher, SG..... S18
Allen, K..... P95	Durrant, LG..... S37	Humphries, MP..... P25
Almasmoum, H..... P36	<b>E</b>	<b>I</b>
Alnabulsi, A..... O12	Ebili, HO..... P126, P127, P128	Ironside, A..... PL1
Alsulaiman, AS..... P37	Elghobashy, M..... P21	Irving, WL..... S38
Amary, MF..... S41	Emmerich, M..... P100	Iyer, VN..... P108
Amoah-Duodo, A..... P7	Evans, M..... P69	<b>J</b>
Anderson, WJ..... P94	<b>F</b>	Jiang, Y..... P26
Arberry, J..... P44	Fahmy, M..... P70	Jimenez-Linan, M..... S45
Arends, MJ..... S4	Fernandez, XM..... S47	Johal, DS..... P101
Asiri, AF..... P39	Flatman, KED..... P122	Johnstone, EL..... P29
Asiri, AM..... P38	Foster, SN..... P123	Joseph, C..... O8, P11, P12
<b>B</b>	Freemont, AJ..... S11	<b>K</b>
Beesley, MF..... P90	<b>G</b>	Karunaratne, KAM..... P109
Bell, C..... P59	Gahlaut, R..... P22, P72, P73	Kerr, KM..... S50
Berney, DM..... S33	Gangadharan, B..... S49	Khan, MM..... P60, P61
Bhudia, RP..... P84	German, AL..... P107	Kilmartin, D..... P57, P89
Bishop, E..... O37	Gill, MS..... P8, P9, P10	Kim, D..... S50
Byers, RJ..... O5	Gosney, JR..... S6	Kluczna, D..... O39
<b>C</b>	Grabsch, HI..... S27	Kotecha, D..... P30
Cane, PJ..... S7	Graham, J..... P96	Kumar, A..... P103
Cardus, B..... O36	Graham, RLJ..... S1	Kumar, R..... P110
Catargiu, D..... P98	Griffin, J..... O34	<b>L</b>
Charnock-Jones, DS..... S13	Grigoriadis, AE..... S42	Lai, JTT..... P3
Christopher, CO..... P99	Gurhan, S..... O9	Lebrun, L..... PL4
Colling, R..... P40, P41, P42	Gutteridge, A..... O33	Lee, AHS..... S29
Collis, SA..... P2		Lee, K..... P27
Cook, S..... P18		Lindsay, DJ..... P115
Cooke, JS..... P19, P54		Loona, A..... O2, P93
Cooper, RA..... P19, P54, P65		Lorente Pons, A..... PL6
Craze, M..... P14		

**PRESENTERS INDEX**

Presenter's name followed by abstract number

<b>M</b>	<b>R</b>	<b>W</b>
Mackay, HL..... P31	Rakha, EA..... P16	Wada, NW..... P106
MacPherson, S..... P66	Rakovic, K..... P47	Walton, TJ..... S34
Magi-Galluzzi, C..... S36	Rashed, H..... P121	Warford, A..... O35
Marchessoux, C..... O20	Richards, AE..... P112	West, KP..... P111
Martinez, P..... O17	Richman, SD..... O11	West, NP, S10, O15, O18, P81, P82
McDonald, SA..... S26	Roberts, ISD..... O41	Whitelaw, CBA..... S14
McNicol, C..... P18	Robinson, M..... S20	Wood, HM..... P130
Meijer, CJL..... S21	Robson, A..... S23	<b>Y</b>
Merchant, W..... S22	Rotimi, O..... O3	Yao, T..... S28
Miligy, I..... P13	Rutledge, JL..... P91	
Miller, TEA..... P124	<b>S</b>	
Milne, K..... P105	Saira, SS..... P52	
Moore, DA..... PL3, P32, P33, P46	Sampson, J..... P125	
Muftah, AA..... O22	Scholes, AL..... P4	
Mukherjee, A..... O23, O24	Shaaban, AM..... O10	
Munonyara, MT..... P24	Sharif, A..... S46	
<b>N</b>	Shaw, EC..... P129	
Nasir, A..... P63, P64, P104	Sheppard, MN..... P1	
Negm, OH..... O6, O13, P76	Shimoda, M..... P78	
Nicholson, AG..... S12	Shipp, DW..... O30	
<b>O</b>	Short, EL..... P58, P79	
Ojiegbe, S..... P15	Sim, B..... P119, P120	
Orah, NO..... O4	Singh, R..... P48	
Orsi, NM..... P97	Skinner, CM..... P102	
Otifi, HO..... P50, P51	Soilleux, EJ..... O40, P43	
<b>P</b>	Sonbul, SN..... O7, O28, P17	
Padayachy, S..... P20, P114	Sottoriva, A..... S24	
Palmer, TG..... PL8	Surrridge, R..... P6	
Parameshwaran, V..... O31	<b>T</b>	
Picton, S..... S48	Taniere, P..... S39	
Pigera, M..... O21	Taylor, M..... O19	
Pillay, N..... S40	Thomas, K..... P34	
Pinder, SE..... S30	Thorpe, H..... PL7, P53	
Psaltis, EP..... P77	Trefor, R..... P87	
Pugh, MR..... PL5, O38	Trépan, AL..... O32	
Puls, F..... S43	Triantafyllou, A..... P67	
<b>Q</b>	Tullett, MA..... P62	
Quinn, AM..... O1	<b>V</b>	
Quirke, P..... S9	Varma, M..... S32	
	Vermeulen, L..... S25	